จำนวนงานวิจัยของศูนย์ความเป็นเลิศทางด้านโรคมะเร็ง โรงพยาบาลพระมงกุฎเกล้า ที่ได้รับการตีพิมพ์ในวารสารทางการแพทย์
(ข้อมูลจาก PubMed/Google Scholar/Crossref ณ วันที่ 15 กันยายน 2568)
แผนกมะเร็งวิทยา กองอายุรกรรม โรงพยาบาลพระมงกุฎเกล้า
6104509
1
vancouver
100
date
desc
62
https://cancercenter.pmk.ac.th/wordpress/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22J6MFJMVD%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thambamroong%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BThambamroong%20T%2C%20Seetalarom%20K%2C%20Saichaemchan%20S%2C%20Peechatanan%20K%2C%20Phavirunsiri%20J%2C%20Prasongsook%20N.%20IMPROVING%20QUALITY%20OF%20LIFE%20IN%20LOCALLY%20ADVANCED%20OR%20ADVANCED%20HEAD%20AND%20NECK%20CANCER%20WITH%20CURCUMIN%20ADD-ON%20TO%20STANDARD%20NUTRITION%20SUPPORT%3A%20A%20SECONDARY%20ANALYSIS%20OF%20THE%20CURCHEXIA%20STUDY.%20J%20Southeast%20Asian%20Med%20Res%20%5BInternet%5D.%202025%20Sept%209%20%5Bcited%202025%20Sept%2015%5D%3B9%3Ae0234.%20Available%20from%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.jseamed.org%5C%2Findex.php%5C%2Fjseamed%5C%2Farticle%5C%2Fview%5C%2F234%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.jseamed.org%5C%2Findex.php%5C%2Fjseamed%5C%2Farticle%5C%2Fview%5C%2F234%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22IMPROVING%20QUALITY%20OF%20LIFE%20IN%20LOCALLY%20ADVANCED%20OR%20ADVANCED%20HEAD%20AND%20NECK%20CANCER%20WITH%20CURCUMIN%20ADD-ON%20TO%20STANDARD%20NUTRITION%20SUPPORT%3A%20A%20SECONDARY%20ANALYSIS%20OF%20THE%20CURCHEXIA%20STUDY%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawasapon%22%2C%22lastName%22%3A%22Thambamroong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kasan%22%2C%22lastName%22%3A%22Seetalarom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siriwimon%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khunthong%22%2C%22lastName%22%3A%22Peechatanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jareanjit%22%2C%22lastName%22%3A%22Phavirunsiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naiyarat%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22%26lt%3Bp%26gt%3B%26lt%3Bstrong%26gt%3BBackground%3A%26lt%3B%5C%2Fstrong%26gt%3B%20Patients%20with%20head%20and%20neck%20cancer%20often%20suffer%20from%20cancer%20anorexia%20and%20cachexia%20syndrome%20%28CAS%29%2C%20which%20severely%20impacts%20their%20quality%20of%20life%20%28QoL%29.%20The%20primary%20CurChexia%20study%20showed%20that%20curcumin%20improved%20muscle%20mass.%20Objectives%3A%20This%20pre-planned%20secondary%20analysis%20evaluated%20the%20effect%20of%20curcumin%20add-on%20therapy%20on%20the%20QoL%20of%20these%20patients.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bp%26gt%3B%26lt%3Bstrong%26gt%3BMethods%3A%26lt%3B%5C%2Fstrong%26gt%3B%20In%20this%20secondary%20analysis%20of%20a%20randomized%2C%20placebo-controlled%20trial%2C%20twenty%20patients%20with%20locally%20advanced%20or%20advanced%20head%20and%20neck%20cancer%20undergoing%20treatment%20and%20diagnosed%20with%20CAS%20were%20randomized%20to%20receive%20either%204%2C000%20mg%20of%20curcumin%20daily%20or%20a%20placebo%2C%20in%20addition%20to%20standard%20nutritional%20support%20for%20eight%20weeks.%20QoL%20was%20assessed%20at%20baseline%2C%20week%204%2C%20and%20week%208%20using%20the%20EORTC%20QLQ-C30%20questionnaire.%20A%20linear%20mixed-effects%20model%20was%20used%20to%20analyze%20changes%20in%20QoL%20scores%20over%20time%20between%20the%20two%20groups.%20A%20retrospective%20power%20calculation%20was%20conducted%20for%20key%20QoL%20domains.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bp%26gt%3B%26lt%3Bstrong%26gt%3BResults%3A%26lt%3B%5C%2Fstrong%26gt%3B%20The%20curcumin%20add-on%20group%20showed%20statistically%20significant%20improvements%20compared%20to%20the%20control%20group%20in%20physical%20functioning%20%28%26lt%3Bem%26gt%3Bp%26lt%3B%5C%2Fem%26gt%3B%20%3D%200.001%29%2C%20emotional%20functioning%20%28%26lt%3Bem%26gt%3Bp%26lt%3B%5C%2Fem%26gt%3B%20%3D%200.023%29%2C%20appetite%20loss%20%28%26lt%3Bem%26gt%3Bp%26lt%3B%5C%2Fem%26gt%3B%20%3D%200.001%29%2C%20and%20pain%20%28%26lt%3Bem%26gt%3Bp%26lt%3B%5C%2Fem%26gt%3B%20%3D%200.033%29.%20No%20significant%20differences%20were%20observed%20in%20global%20health%20status%20or%20other%20functional%20and%20symptom%20scales.%20The%20study%20was%20adequately%20powered%20%28%26amp%3Bgt%3B80%25%29%20to%20detect%20the%20observed%20significant%20differences%2C%20but%20was%20underpowered%20for%20non-significant%20outcomes%20like%20global%20health%20status.%26lt%3B%5C%2Fp%26gt%3B%26lt%3Bp%26gt%3B%26lt%3Bstrong%26gt%3BConclusion%3A%26lt%3B%5C%2Fstrong%26gt%3B%20In%20patients%20with%20locally%20advanced%20or%20advanced%20head%20and%20neck%20cancer%20experiencing%20cancer%20anorexia-cachexia%20syndrome%20%28CAS%29%20during%20treatment%2C%20the%20addition%20of%20a%20daily%204%2C000%20mg%20dose%20of%20curcumin%20to%20standard%20nutritional%20intervention%20significantly%20improves%20quality%20of%20life%20and%20body%20composition.%20These%20findings%20suggest%20that%20curcumin%20may%20serve%20as%20an%20effective%20pharmaconutrient%2C%20providing%20both%20clinical%20benefits%20and%20supportive%20care.%26lt%3B%5C%2Fp%26gt%3B%22%2C%22date%22%3A%222025-09-09%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.55374%5C%2Fjseamed.v9.234%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.jseamed.org%5C%2Findex.php%5C%2Fjseamed%5C%2Farticle%5C%2Fview%5C%2F234%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-09-15T07%3A14%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22BNZISENP%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shuangshoti%20et%20al.%22%2C%22parsedDate%22%3A%222025-07-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BShuangshoti%20S%2C%20Prasongsook%20N%2C%20Thamlikitkul%20L%2C%20Reungwetwattana%20T%2C%20Poungvarin%20N%2C%20Jinawath%20A%2C%20et%20al.%20Expert%20recommendations%20for%20biomarker%20evaluation%20of%20advanced%20non-small%20cell%20lung%20cancer%20in%20Thailand.%20Transl%20Lung%20Cancer%20Res.%202025%20July%2031%3B14%287%29%3A2387%26%23x2013%3B402.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expert%20recommendations%20for%20biomarker%20evaluation%20of%20advanced%20non-small%20cell%20lung%20cancer%20in%20Thailand%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Shuangshoti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Thamlikitkul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Reungwetwattana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Poungvarin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jinawath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Teerapakpinyo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Vinyuvat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Sriuranpong%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Growing%20understanding%20of%20the%20heterogenous%20molecular%20profiles%20of%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20has%20led%20to%20changes%20in%20the%20treatment%20landscape%20of%20advanced%20NSCLC%20towards%20precision%20medicine%20to%20target%20actionable%20gene%20alterations.%20Practical%20barriers%2C%20such%20as%20lack%20of%20awareness%5C%2Funderstanding%20of%20biomarkers%2C%20suboptimal%20quality%20or%20sample%20management%2C%20inappropriate%20use%20of%20biomarker%20testing%20results%2C%20limited%20patient%20access%20to%20biomarker%20tests%20and%20targeted%20treatments%2C%20and%20reimbursement%5C%2Fpayment%20challenges%2C%20hinder%20the%20wider%20adoption%20of%20guideline-recommended%20biomarker%20testing.%20Limited%20reimbursement%20of%20targeted%20therapies%20is%20a%20key%20consideration%20for%20Thai%20oncologists%20when%20making%20a%20treatment%20choice%20for%20their%20patients%20with%20advanced%20NSCLC%20in%20Thailand.%20We%20aim%20to%20assess%20the%20current%20state%20of%20biomarker%20testing%20and%20treatment%20for%20advanced%20NSCLC%20in%20Thailand%20and%20provide%20recommendations%20to%20facilitate%20timely%20access%20to%20appropriate%20therapies%2C%20enhance%20patient%20quality%20of%20life%2C%20and%20optimize%20the%20use%20of%20Thailand%26%23039%3Bs%20existing%20healthcare%20schemes.%20METHODS%3A%20The%20expert%20panel%20comprising%20one%20clinical%20pathologist%2C%20three%20anatomic%20pathologists%2C%20one%20molecular%20geneticist%2C%20and%20four%20medical%20oncologists%20convened%20to%20review%20recent%20literature%2C%20discuss%20current%20clinical%20practice%2C%20and%20prioritize%20essential%20topics%20for%20biomarker%20assessment%20and%20management%20of%20advanced%20NSCLC%20in%20Thailand.%20Following%20the%20meeting%2C%20further%20discussions%20on%20these%20prioritized%20topics%20were%20conducted%20via%20email%2C%20and%20the%20recommendations%20were%20developed.%20RESULTS%3A%20Our%20recommendations%20include%20adopting%20an%20exclusionary%20strategy%20for%20biomarker%20testing%2C%20emphasizing%20the%20role%20of%20a%20multidisciplinary%20team%20%28MDT%29%20in%20managing%20patients%20with%20advanced%20NSCLC%2C%20and%20underscoring%20the%20importance%20of%20laboratory%20accreditation%20and%20external%20quality%20assurance%20programs.%20Additionally%2C%20we%20highlight%20the%20need%20for%20high-quality%20data%20on%20the%20local%20impact%20of%20novel%20treatments%20to%20assist%20policymakers%20in%20making%20these%20therapies%20accessible%20to%20suitable%20patients.%20CONCLUSIONS%3A%20By%20proposing%20practical%20strategies%20tailored%20to%20our%20local%20healthcare%20setting%2C%20such%20as%20exclusionary%20biomarker%20testing%20approach%2C%20MDT%20involvement%2C%20and%20robust%20quality%20assurance%20measures%2C%20we%20provide%20a%20roadmap%20for%20improving%20the%20diagnosis%20and%20treatment%20of%20advanced%20NSCLC.%22%2C%22date%22%3A%22Jul%2031%202025%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.21037%5C%2Ftlcr-2025-201%22%2C%22ISSN%22%3A%222218-6751%20%28Print%29%202226-4477%20%28Electronic%29%202218-6751%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22TLZHAXA7%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kanesvaran%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKanesvaran%20R%2C%20Wong%20EYT%2C%20Keam%20B%2C%20Prasongsook%20N%2C%20Malhotra%20H%2C%20Blay%20JY.%20Quality-of-care%20indicators%20for%20oncology%20management%3A%20an%20analysis%20of%20Asia-Pacific%20healthcare%20and%20oncology%20indicators.%20ESMO%20Open.%202025%20Mar%3B10%283%29%3A104293.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quality-of-care%20indicators%20for%20oncology%20management%3A%20an%20analysis%20of%20Asia-Pacific%20healthcare%20and%20oncology%20indicators%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kanesvaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Y.%20T.%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Keam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Malhotra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22Cancer%20is%20a%20major%20cause%20of%20morbidity%20and%20mortality%2C%20with%20variable%20outcomes%20seen%20in%20the%20Asia-Pacific%20region%20due%20to%20substantial%20differences%20in%20cancer%20care%20and%20management.%20Quality%20indicators%20are%20evidence-based%2C%20standardized%20measures%20of%20healthcare%20quality%20that%20help%20measure%20or%20quantify%20healthcare%20processes%2C%20outcomes%2C%20and%20organizational%20systems%20to%20help%20promote%20and%20provide%20equitable%20high-quality%20healthcare.%20A%20detailed%20list%20of%20quality%20indicators%20in%20medical%2C%20surgical%2C%20and%20palliative%20oncology%20was%20identified%20from%20literature%20reviews.%20This%20study%2C%20which%20was%20commissioned%20by%20the%20ESMO%20Asia%20Pacific%20Public%20Policy%20Committee%2C%20aims%20to%20report%20on%20the%20performance%20of%20healthcare%20and%20oncology%20quality%20indicators%20across%2047%20countries%20in%20the%20Asia-Pacific%20region.%22%2C%22date%22%3A%22Mar%202025%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2025.104293%22%2C%22ISSN%22%3A%222059-7029%20%28Electronic%29%202059-7029%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22QLE3IGBQ%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Crona%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCrona%20J%2C%20Lee%20R%2C%20Sobczuk%20P%2C%20Wysoki%20O%2C%20Devnani%20B%2C%20Prasongsook%20N%2C%20et%20al.%20Reinventing%20ESMO%20after%20the%20COVID-19%20pandemic%3A%20moving%20towards%20a%20sustainable%20academic%20society.%20ESMO%20Open.%202024%20May%3B9%285%29%3A102531.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reinventing%20ESMO%20after%20the%20COVID-19%20pandemic%3A%20moving%20towards%20a%20sustainable%20academic%20society%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Crona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sobczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Wysoki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Devnani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Scheffler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jalving%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Esmo%20Climate%20Change%20Task%20Force%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2024.102531%22%2C%22ISSN%22%3A%222059-7029%20%28Electronic%29%202059-7029%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%226W5ZQF67%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gobbo%20et%20al.%22%2C%22parsedDate%22%3A%222024-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGobbo%20M%2C%20Joy%20J%2C%20Guedes%20H%2C%20Shazib%20MA%2C%20Anderson%20C%2C%20Abdalla-Aslan%20R%2C%20et%20al.%20Emerging%20pharmacotherapy%20trends%20in%20preventing%20and%20managing%20oral%20mucositis%20induced%20by%20chemoradiotherapy%20and%20targeted%20agents.%20Expert%20Opin%20Pharmacother.%202024%20Apr%3B25%286%29%3A727%26%23x2013%3B42.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Emerging%20pharmacotherapy%20trends%20in%20preventing%20and%20managing%20oral%20mucositis%20induced%20by%20chemoradiotherapy%20and%20targeted%20agents%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Gobbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Joy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Guedes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Shazib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Abdalla-Aslan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Peechatanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lajolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20S.%22%2C%22lastName%22%3A%22Nasir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Gueiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Nagarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Hafezi%20Motlagh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kandwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Rupe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20D.%22%2C%22lastName%22%3A%22Ehrenpreis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Tonkaboni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Epstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Bossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20R.%22%2C%22lastName%22%3A%22Wardill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Graff%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20introduction%20of%20targeted%20therapy%20and%20immunotherapy%20has%20tremendously%20changed%20the%20clinical%20outcomes%20and%20prognosis%20of%20cancer%20patients.%20Despite%20innovative%20pharmacological%20therapies%20and%20improved%20radiotherapy%20%28RT%29%20techniques%2C%20patients%20continue%20to%20suffer%20from%20side%20effects%2C%20of%20which%20oral%20mucositis%20%28OM%29%20is%20still%20the%20most%20impactful%2C%20especially%20for%20quality%20of%20life.%20AREAS%20COVERED%3A%20We%20provide%20an%20overview%20of%20current%20advances%20in%20cancer%20pharmacotherapy%20and%20RT%2C%20in%20relation%20to%20their%20potential%20to%20cause%20OM%2C%20and%20of%20the%20less%20explored%20and%20more%20recent%20literature%20reports%20related%20to%20the%20best%20management%20of%20OM.%20We%20have%20analyzed%20natural%5C%2Fantioxidant%20agents%2C%20probiotics%2C%20mucosal%20protectants%20and%20healing%20coadjuvants%2C%20pharmacotherapies%2C%20immunomodulatory%20and%20anticancer%20agents%2C%20photobiomodulation%20and%20the%20impact%20of%20technology.%20EXPERT%20OPINION%3A%20The%20discovery%20of%20more%20precise%20pathophysiologic%20mechanisms%20of%20CT%20and%20RT-induced%20OM%20has%20outlined%20that%20OM%20has%20a%20multifactorial%20origin%2C%20including%20direct%20effects%2C%20oxidative%20damage%2C%20upregulation%20of%20immunologic%20factors%2C%20and%20effects%20on%20oral%20flora.%20A%20persistent%20upregulated%20immune%20response%2C%20associated%20with%20factors%20related%20to%20patients%26%23039%3B%20characteristics%2C%20may%20contribute%20to%20more%20severe%20and%20long-lasting%20OM.%20The%20goal%20is%20strategies%20to%20conjugate%20individual%20patient%2C%20disease%2C%20and%20therapy-related%20factors%20to%20guide%20OM%20prevention%20or%20treatment.%20Despite%20further%20high-quality%20research%20is%20warranted%2C%20the%20issue%20of%20prevention%20is%20paramount%20in%20future%20strategies.%22%2C%22date%22%3A%22Apr%202024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F14656566.2024.2354451%22%2C%22ISSN%22%3A%221744-7666%20%28Electronic%29%201465-6566%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%222IDP7KGG%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thambamroong%20and%20Rabiltossaporn%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BThambamroong%20T%2C%20Rabiltossaporn%20C.%20Biallelic%20MUTYH%20gene%20mutation%20resulting%20in%20fluoropyrimidine-resistant%20advanced%20rectal%20cancer%3A%20A%20case%20report.%20TD%20%5BInternet%5D.%202024%3B4%281%29.%20Available%20from%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3B%7Bhttps%3A%5C%2F%5C%2Faccscience.com%5C%2F%5C%2Fjournal%5C%2FTD%5C%2F4%5C%2F1%5C%2F10.36922%5C%2Ftd.5164%7D%26%23039%3B%26gt%3B%7Bhttps%3A%5C%2F%5C%2Faccscience.com%5C%2F%5C%2Fjournal%5C%2FTD%5C%2F4%5C%2F1%5C%2F10.36922%5C%2Ftd.5164%7D%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Biallelic%20MUTYH%20gene%20mutation%20resulting%20in%20fluoropyrimidine-resistant%20advanced%20rectal%20cancer%3A%20A%20case%20report%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawasapon%22%2C%22lastName%22%3A%22Thambamroong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chawanya%22%2C%22lastName%22%3A%22Rabiltossaporn%22%7D%5D%2C%22abstractNote%22%3A%22%26lt%3Bp%20style%3D%26quot%3Btext-align%3A%20justify%3B%26quot%3B%26gt%3BColorectal%20cancer%20%28CRC%29%20is%20a%20leading%20cause%20of%20cancer-related%20mortality%20worldwide%20and%20the%20third%20most%20common%20cancer%20in%20Thailand.%20Approximately%202%25%20%26ndash%3B%205%25%20of%20CRC%20cases%20are%20associated%20with%20inherited%20cancer%20syndromes%2C%20whereas%20the%20majority%20is%20sporadic.%20Herein%2C%20we%20have%20reported%20the%20case%20of%20a%2032-year-old%20male%20with%20poorly%20differentiated%20middle%20rectal%20adenocarcinoma%20%28T4bN1M1%2C%20Stage%20IV%29%20that%20was%20refractory%20to%20fluoropyrimidine-based%20chemotherapy.%20Genetic%20profiling%20revealed%20a%20homozygous%20c.934-2A%26gt%3BG%20mutation%20in%20the%20%26lt%3Bem%26gt%3BMUTYH%20%26lt%3B%5C%2Fem%26gt%3Bgene%2C%20which%20disrupted%20the%20DNA%20repair.%20Despite%20palliative%20radiation%20%2830%20Gy%20in%2010%20fractions%29%20and%20systemic%20therapies%20%28capecitabine%20plus%20oxaliplatin%20%2B%20panitumumab%20and%20fluorouracil%2C%20leucovorin%2C%20and%20irinotecan%20%2B%20bevacizumab%29%2C%20the%20disease%20progressed%20rapidly.%20Third-line%20therapy%20with%20Irinotecan%20plus%20oxaliplatin%20demonstrated%20initial%20success%20%28partial%20response%29.%20Eventually%2C%20disease%20progression%20ensued.%20This%20report%20highlights%20the%20challenges%20of%20managing%20CRC%20caused%20by%20biallelic%20%26lt%3Bem%26gt%3BMUTYH%20%26lt%3B%5C%2Fem%26gt%3Bmutations%20and%20emphasizes%20the%20importance%20of%20comprehensive%20genomic%20profiling%20for%20guiding%20therapeutic%20decisions.%20A%20review%20of%20similar%20cases%20in%20the%20literature%20is%20also%20presented.%26lt%3B%5C%2Fp%26gt%3B%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%7Bhttps%3A%5C%2F%5C%2Faccscience.com%5C%2F%5C%2Fjournal%5C%2FTD%5C%2F4%5C%2F1%5C%2F10.36922%5C%2Ftd.5164%7D%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-09-15T07%3A18%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22JNGBLF9G%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Loong%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLoong%20HH%2C%20Shimizu%20T%2C%20Prawira%20A%2C%20Tan%20AC%2C%20Tran%20B%2C%20Day%20D%2C%20et%20al.%20Recommendations%20for%20the%20use%20of%20next-generation%20sequencing%20in%20patients%20with%20metastatic%20cancer%20in%20the%20Asia-Pacific%20region%3A%20a%20report%20from%20the%20APODDC%20working%20group.%20ESMO%20Open.%202023%20Aug%3B8%284%29%3A101586.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recommendations%20for%20the%20use%20of%20next-generation%20sequencing%20in%20patients%20with%20metastatic%20cancer%20in%20the%20Asia-Pacific%20region%3A%20a%20report%20from%20the%20APODDC%20working%20group%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20H.%22%2C%22lastName%22%3A%22Loong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shimizu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Prawira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Day%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%20P.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20I.%20L.%22%2C%22lastName%22%3A%22Ting%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Chiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Koyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Reungwetwattana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20J.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Heong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Voon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20B.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%20W.%22%2C%22lastName%22%3A%22Tan%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Next-generation%20sequencing%20%28NGS%29%20diagnostics%20have%20shown%20clinical%20utility%20in%20predicting%20survival%20benefits%20in%20patients%20with%20certain%20cancer%20types%20who%20are%20undergoing%20targeted%20drug%20therapies.%20Currently%2C%20there%20are%20no%20guidelines%20or%20recommendations%20for%20the%20use%20of%20NGS%20in%20patients%20with%20metastatic%20cancer%20from%20an%20Asian%20perspective.%20In%20this%20article%2C%20we%20present%20the%20Asia-Pacific%20Oncology%20Drug%20Development%20Consortium%20%28APODDC%29%20recommendations%20for%20the%20clinical%20use%20of%20NGS%20in%20metastatic%20cancers.%20METHODS%3A%20The%20APODDC%20set%20up%20a%20group%20of%20experts%20in%20the%20field%20of%20clinical%20cancer%20genomics%20to%20%28i%29%20understand%20the%20current%20NGS%20landscape%20for%20metastatic%20cancers%20in%20the%20Asia-Pacific%20%28APAC%29%20region%3B%20%28ii%29%20discuss%20key%20challenges%20in%20the%20adoption%20of%20NGS%20testing%20in%20clinical%20practice%3B%20and%20%28iii%29%20adapt%5C%2Fmodify%20the%20European%20Society%20for%20Medical%20Oncology%20guidelines%20for%20local%20use.%20Nine%20cancer%20types%20%5Bbreast%20cancer%20%28BC%29%2C%20gastric%20cancer%20%28GC%29%2C%20nasopharyngeal%20cancer%20%28NPC%29%2C%20ovarian%20cancer%20%28OC%29%2C%20prostate%20cancer%2C%20lung%20cancer%2C%20and%20colorectal%20cancer%20%28CRC%29%20as%20well%20as%20cholangiocarcinoma%20and%20hepatocellular%20carcinoma%20%28HCC%29%5D%20were%20identified%2C%20and%20the%20applicability%20of%20NGS%20was%20evaluated%20in%20daily%20practice%20and%5C%2For%20clinical%20research.%20Asian%20ethnicity%2C%20accessibility%20of%20NGS%20testing%2C%20reimbursement%2C%20and%20socioeconomic%20and%20local%20practice%20characteristics%20were%20taken%20into%20consideration.%20RESULTS%3A%20The%20APODDC%20recommends%20NGS%20testing%20in%20metastatic%20non-small-cell%20lung%20cancer%20%28NSCLC%29.%20Routine%20NGS%20testing%20is%20not%20recommended%20in%20metastatic%20BC%2C%20GC%2C%20and%20NPC%20as%20well%20as%20cholangiocarcinoma%20and%20HCC.%20The%20group%20suggested%20that%20patients%20with%20epithelial%20OC%20may%20be%20offered%20germline%20and%5C%2For%20somatic%20genetic%20testing%20for%20BReast%20CAncer%20gene%201%20%28BRCA1%29%2C%20BRCA2%2C%20and%20other%20OC%20susceptibility%20genes.%20Access%20to%20poly%20%28ADP-ribose%29%20polymerase%20inhibitors%20is%20required%20for%20NGS%20to%20be%20of%20clinical%20utility%20in%20prostate%20cancer.%20Allele-specific%20PCR%20or%20a%20small-panel%20multiplex-gene%20NGS%20was%20suggested%20to%20identify%20key%20alterations%20in%20CRC.%20CONCLUSION%3A%20This%20document%20offers%20practical%20guidance%20on%20the%20clinical%20utility%20of%20NGS%20in%20specific%20cancer%20indications%20from%20an%20Asian%20perspective.%22%2C%22date%22%3A%22Aug%202023%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2023.101586%22%2C%22ISSN%22%3A%222059-7029%20%28Electronic%29%202059-7029%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22H7HHQXMT%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yoshino%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BYoshino%20T%2C%20Cervantes%20A%2C%20Bando%20H%2C%20Martinelli%20E%2C%20Oki%20E%2C%20Xu%20RH%2C%20et%20al.%20Pan-Asian%20adapted%20ESMO%20Clinical%20Practice%20Guidelines%20for%20the%20diagnosis%2C%20treatment%20and%20follow-up%20of%20patients%20with%20metastatic%20colorectal%20cancer.%20ESMO%20Open.%202023%20June%3B8%283%29%3A101558.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pan-Asian%20adapted%20ESMO%20Clinical%20Practice%20Guidelines%20for%20the%20diagnosis%2C%20treatment%20and%20follow-up%20of%20patients%20with%20metastatic%20colorectal%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Yoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Cervantes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Martinelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Oki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20H.%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20A.%22%2C%22lastName%22%3A%22Mulansari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Govind%20Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20K.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Cornelio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20Q.%22%2C%22lastName%22%3A%22Chong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20T.%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tanasanvimon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20H.%22%2C%22lastName%22%3A%22Yeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20D.%22%2C%22lastName%22%3A%22Sacdalan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20J.%22%2C%22lastName%22%3A%22Sow%20Jenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20T.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20T.%22%2C%22lastName%22%3A%22Chacko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20A.%22%2C%22lastName%22%3A%22Syaiful%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20Z.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Curigliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Mishima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Nakamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Ebi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Sunakawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Takahashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Baba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ishioka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Pentheroudakis%22%7D%5D%2C%22abstractNote%22%3A%22The%20European%20Society%20for%20Medical%20Oncology%20%28ESMO%29%20Clinical%20Practice%20Guidelines%20for%20the%20diagnosis%2C%20treatment%20and%20follow-up%20of%20patients%20with%20metastatic%20colorectal%20cancer%20%28mCRC%29%2C%20published%20in%20late%202022%2C%20were%20adapted%20in%20December%202022%2C%20according%20to%20previously%20established%20standard%20methodology%2C%20to%20produce%20the%20Pan-Asian%20adapted%20%28PAGA%29%20ESMO%20consensus%20guidelines%20for%20the%20management%20of%20Asian%20patients%20with%20mCRC.%20The%20adapted%20guidelines%20presented%20in%20this%20manuscript%20represent%20the%20consensus%20opinions%20reached%20by%20a%20panel%20of%20Asian%20experts%20in%20the%20treatment%20of%20patients%20with%20mCRC%20representing%20the%20oncological%20societies%20of%20China%20%28CSCO%29%2C%20Indonesia%20%28ISHMO%29%2C%20India%20%28ISMPO%29%2C%20Japan%20%28JSMO%29%2C%20Korea%20%28KSMO%29%2C%20Malaysia%20%28MOS%29%2C%20the%20Philippines%20%28PSMO%29%2C%20Singapore%20%28SSO%29%2C%20Taiwan%20%28TOS%29%20and%20Thailand%20%28TSCO%29%2C%20co-ordinated%20by%20ESMO%20and%20the%20Japanese%20Society%20of%20Medical%20Oncology%20%28JSMO%29.%20The%20voting%20was%20based%20on%20scientific%20evidence%20and%20was%20independent%20of%20the%20current%20treatment%20practices%2C%20drug%20access%20restrictions%20and%20reimbursement%20decisions%20in%20the%20different%20Asian%20countries.%20The%20latter%20are%20discussed%20separately%20in%20the%20manuscript.%20The%20aim%20is%20to%20provide%20guidance%20for%20the%20optimisation%20and%20harmonisation%20of%20the%20management%20of%20patients%20with%20mCRC%20across%20the%20different%20countries%20of%20Asia%2C%20drawing%20on%20the%20evidence%20provided%20by%20both%20Western%20and%20Asian%20trials%2C%20whilst%20respecting%20the%20differences%20in%20screening%20practices%2C%20molecular%20profiling%20and%20age%20and%20stage%20at%20presentation%2C%20coupled%20with%20a%20disparity%20in%20the%20drug%20approvals%20and%20reimbursement%20strategies%2C%20between%20the%20different%20countries.%22%2C%22date%22%3A%22Jun%202023%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2023.101558%22%2C%22ISSN%22%3A%222059-7029%20%28Electronic%29%202059-7029%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22C8NC24XL%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pornrattanakavee%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPornrattanakavee%20P%2C%20Srichan%20T%2C%20Seetalarom%20K%2C%20Saichaemchan%20S%2C%20Oer-Areemitr%20N%2C%20Prasongsook%20N.%20Impact%20of%20interprofessional%20collaborative%20practice%20in%20palliative%20care%20on%20outcomes%20for%20advanced%20cancer%20inpatients%20in%20a%20resource-limited%20setting.%20BMC%20Palliat%20Care.%202022%20Dec%2029%3B21%281%29%3A229.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20interprofessional%20collaborative%20practice%20in%20palliative%20care%20on%20outcomes%20for%20advanced%20cancer%20inpatients%20in%20a%20resource-limited%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Pornrattanakavee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Srichan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Seetalarom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Oer-Areemitr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Palliative%20care%20for%20patients%20with%20advanced%20cancer%20improves%20suffering%20symptoms%2C%20and%20quality%20of%20life%20%28QoL%29.%20However%2C%20routine%20implementation%20of%20palliative%20care%20by%20specialty%20palliative%20care%20consultation%20is%20still%20an%20unmet%20need%20among%20in-patients%20with%20advanced%20cancer.%20Our%20study%20aim%20is%20to%20evaluate%20the%20effectiveness%20of%20a%20team-based%20approach%20on%20QoLs%20and%20readmission%20rate%20when%20compared%20to%20routine%20practice%20by%20among%20medical%20oncologists.%20METHODS%3A%20This%20study%20was%20a%20prospective%2C%20Quasi-Experimental%20design.%20In-patients%20with%20advanced%20cancer%20were%20non-randomly%20assigned%20to%20receive%20palliative%20care%20service%20by%20team-based%20approach%20or%20medical%20oncologists%20only.%20The%20primary%20endpoint%20was%20QoL.%20The%20secondary%20endpoint%20was%20the%20readmission%20rate%20at%207%20and%2030%20days%20of%20hospital%20discharge.%20RESULTS%3A%20One%20hundred%20twenty-two%20in-patients%20were%20enrolled.%20In-patients%20who%20were%20assessed%20by%20a%20team-based%20approach%20had%20significantly%20improved%20change%20scores%20of%20subjective%20well-being%20%28SWB%29%20when%20compared%20to%20another%20group%20%28%5Cu2206%20SWB%3A%20-1%20%5B-19%20-%2011%5D%20vs%200%20%5B-9%20-%2015%5D%2C%20p-value%20%3D%200.043%29.%20Furthermore%2C%20patients%20who%20were%20assessed%20under%20a%20team-based%20approach%20had%20significantly%20decreased%20in%20terms%20of%20readmission%20rate%20at%207%20days%20of%20hospital%20discharge%20%284.92%25%20in%20the%20team-based%20approach%20group%20vs.%2019.67%25%20in%20the%20medical%20oncologist%20group%2C%20p-value%20%3D%200.013%29.%20CONCLUSIONS%3A%20Interdisciplinary%20collaboration%20is%20the%20key%20to%20success%20in%20establishing%20goals%20of%20care%2C%20which%20are%20supporting%20the%20best%20possible%20QoL%20and%20relieving%20suffering%20symptoms%20for%20those%20in-patients%20with%20advanced%20cancer.%20Furthermore%2C%20the%20readmission%20rate%20at%207%20days%20of%20hospital%20discharge%20was%20significantly%20reduced%20by%20a%20team-based%20approach.%20Therefore%2C%20comprehensive%20palliative%20care%20assessment%20by%20interprofessional%20collaborative%20practice%20is%20required.%20TRIAL%20REGISTRATION%3A%20Thai%20Clinical%20Trials%20Registry%20%28TCTR%29%3A%20number%2020200312001.%20Date%20of%20first%20registration%20on%2009%5C%2F03%5C%2F2020.%22%2C%22date%22%3A%22Dec%2029%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12904-022-01121-0%22%2C%22ISSN%22%3A%221472-684X%20%28Electronic%29%201472-684X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A46Z%22%7D%7D%2C%7B%22key%22%3A%226LMGULHD%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ahn%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAhn%20MJ%2C%20Mendoza%20MJL%2C%20Pavlakis%20N%2C%20Kato%20T%2C%20Soo%20RA%2C%20Kim%20DW%2C%20et%20al.%20Asian%20Thoracic%20Oncology%20Research%20Group%20%28ATORG%29%20Expert%20Consensus%20Statement%20on%20MET%20Alterations%20in%20NSCLC%3A%20Diagnostic%20and%20Therapeutic%20Considerations.%20Clin%20Lung%20Cancer.%202022%20Dec%3B23%288%29%3A670%26%23x2013%3B85.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Asian%20Thoracic%20Oncology%20Research%20Group%20%28ATORG%29%20Expert%20Consensus%20Statement%20on%20MET%20Alterations%20in%20NSCLC%3A%20Diagnostic%20and%20Therapeutic%20Considerations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Ahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%20L.%22%2C%22lastName%22%3A%22Mendoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pavlakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Kato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20A.%22%2C%22lastName%22%3A%22Soo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20W.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20K.%22%2C%22lastName%22%3A%22Liam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20C.%22%2C%22lastName%22%3A%22Hsia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20K.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Reungwetwattana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Geater%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20S.%20H.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20T.%20H.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Kozuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20L.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20S.%20K.%22%2C%22lastName%22%3A%22Mok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Yatabe%22%7D%5D%2C%22abstractNote%22%3A%22Non-small%20cell%20lung%20cancer%20%28NSCLC%29%20is%20a%20heterogeneous%20disease%2C%20with%20many%20oncogenic%20driver%20mutations%2C%20including%20de%20novo%20mutations%20in%20the%20Mesenchymal%20Epithelial%20Transition%20%28MET%29%20gene%20%28specifically%20in%20Exon%2014%20%5Bex14%5D%29%2C%20that%20lead%20to%20tumourigenesis.%20Acquired%20alterations%20in%20the%20MET%20gene%2C%20specifically%20MET%20amplification%20is%20also%20associated%20with%20the%20development%20of%20epidermal%20growth%20factor%20receptor%20%28EGFR%29%20tyrosine%20kinase%20inhibitor%20%28TKI%29%20resistance%20in%20patients%20with%20EGFR-mutant%20NSCLC.%20Although%20MET%20has%20become%20an%20actionable%20biomarker%20with%20the%20availability%20of%20MET-specific%20inhibitors%20in%20selected%20countries%2C%20there%20is%20differential%20accessibility%20to%20diagnostic%20platforms%20and%20targeted%20therapies%20across%20countries%20in%20Asia-Pacific%20%28APAC%29.%20The%20Asian%20Thoracic%20Oncology%20Research%20Group%20%28ATORG%29%2C%20an%20interdisciplinary%20group%20of%20experts%20from%20Australia%2C%20Hong%20Kong%2C%20Japan%2C%20Korea%2C%20Mainland%20China%2C%20Malaysia%2C%20the%20Philippines%2C%20Singapore%2C%20Taiwan%2C%20Thailand%20and%20Vietnam%2C%20discussed%20testing%20for%20MET%20alterations%20and%20considerations%20for%20using%20MET-specific%20inhibitors%20at%20a%20consensus%20meeting%20in%20January%202022%2C%20and%20in%20subsequent%20offline%20consultation.%20Consensus%20recommendations%20are%20provided%20by%20the%20ATORG%20group%20to%20address%20the%20unmet%20need%20for%20standardised%20approaches%20to%20diagnosing%20MET%20alterations%20in%20NSCLC%20and%20for%20using%20these%20therapies.%20MET%20inhibitors%20may%20be%20considered%20for%20first-line%20or%20second%20or%20subsequent%20lines%20of%20treatment%20for%20patients%20with%20advanced%20and%20metastatic%20NSCLC%20harbouring%20MET%20ex14%20skipping%20mutations%3B%20MET%20ex14%20testing%20is%20preferred%20within%20multi-gene%20panels%20for%20detecting%20targetable%20driver%20mutations%20in%20NSCLC.%20For%20patients%20with%20EGFR-mutant%20NSCLC%20and%20MET%20amplification%20leading%20to%20EGFR%20TKI%20resistance%2C%20enrolment%20in%20combination%20trials%20of%20EGFR%20TKIs%20and%20MET%20inhibitors%20is%20encouraged.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cllc.2022.07.012%22%2C%22ISSN%22%3A%221938-0690%20%28Electronic%29%201525-7304%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22P9V8FVHR%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Charonpongsuntorn%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCharonpongsuntorn%20C%2C%20Tanasanvimon%20S%2C%20Korphaisarn%20K%2C%20Payapwattanawong%20S%2C%20Siripoon%20T%2C%20Pakvisal%20N%2C%20et%20al.%20Efficacy%2C%20Safety%2C%20and%20Patient-Reported%20Outcomes%20of%20Atezolizumab%20Plus%20Bevacizumab%20for%20Unresectable%20Hepatocellular%20Carcinoma%20in%20Thailand%3A%20A%20Multicenter%20Prospective%20Study.%20JCO%20Glob%20Oncol.%202022%20Nov%3B8%3Ae2200205.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%2C%20Safety%2C%20and%20Patient-Reported%20Outcomes%20of%20Atezolizumab%20Plus%20Bevacizumab%20for%20Unresectable%20Hepatocellular%20Carcinoma%20in%20Thailand%3A%20A%20Multicenter%20Prospective%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Charonpongsuntorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tanasanvimon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Korphaisarn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Payapwattanawong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Siripoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pakvisal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Juengsamarn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Phaibulvatanapong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Chindaprasirt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Udomdamrongkul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ngamphaiboon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sirachainan%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Atezolizumab%20plus%20bevacizumab%20treatment%20is%20a%20first-line%20therapy%20for%20unresectable%20hepatocellular%20carcinoma%20%28HCC%29%20worldwide.%20The%20efficacy%2C%20safety%2C%20and%20patient-reported%20outcomes%20%28PROs%29%20of%20HCC%20in%20Thailand%20have%20not%20yet%20been%20reported.%20This%20study%20aimed%20to%20evaluate%20the%20efficacy%2C%20safety%2C%20and%20PROs%20of%20atezolizumab%20plus%20bevacizumab.%20MATERIALS%20AND%20METHODS%3A%20From%20September%202020%20to%20August%202021%2C%2030%20patients%20with%20unresectable%20HCC%20who%20met%20the%20inclusion%20criteria%20of%20atezolizumab%20plus%20bevacizumab%20as%20first-line%20treatment%20were%20enrolled.%20Analysis%20was%20assessed%20for%20progression-free%20survival%2C%20overall%20survival%2C%20adverse%20events%20%28AEs%29%2C%20and%20quality%20of%20life%20%28QoL%29.%20RESULTS%3A%20The%20median%20progression-free%20survival%20and%20overall%20survival%20periods%20were%206.7%20and%2010.2%20months%2C%20respectively.%20The%20disease%20control%20rate%20was%2063.3%25.%20The%20frequent%20AEs%20were%20proteinuria%2C%20hypertension%2C%20and%20hepatitis.%20Serious%20AEs%20included%20gastrointestinal%20bleeding%2C%20but%20none%20of%20the%20patients%20died%20from%20serious%20AEs.%20The%20discontinuation%20rate%20was%2023.3%25%2C%20and%20the%20median%20number%20of%20treatment%20cycles%20was%2010.5%20cycles.%20In%20total%2C%2023.3%25%20of%20the%20patients%20continued%20treatment%20after%201%20year%20of%20therapy.%20The%20global%20health%20status%5C%2FQoL%20and%20physical%20function%20scores%20showed%20less%20deterioration%20at%20baseline%20than%20at%203%20and%206%20months%20%28median%20scores%20%3D%2076.7%2C%2071.6%2C%20and%2064.1%20in%20QoL%20and%2084.7%2C%2079.6%2C%20and%2079.0%20in%20physical%20function%2C%20respectively%29.%20The%20HCC18%20symptom%20score%20index%20data%20showed%20a%20slow%20progression%20of%20symptom%20scores%20from%20baseline%20to%203%20and%206%20months%20%2812.7%2C%2019.6%2C%20and%2022.3%2C%20respectively%29.%20CONCLUSION%3A%20This%20study%20demonstrates%20that%20atezolizumab%20plus%20bevacizumab%20is%20effective%20and%20has%20a%20safety%20profile%20comparable%20with%20that%20of%20previous%20studies%20as%20first-line%20therapy%20for%20unresectable%20HCC%20in%20a%20real-world%20setting%20and%20in%20Thai%20populations.%20Data%20on%20PROs%20also%20demonstrate%20benefits%20in%20terms%20of%20patients%26%23039%3B%20QoL%20and%20symptoms.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1200%5C%2FGO.22.00205%22%2C%22ISSN%22%3A%222687-8941%20%28Electronic%29%202687-8941%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22WXZGU7FT%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Soo%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSoo%20R%2C%20Mery%20L%2C%20Bardot%20A%2C%20Kanesvaran%20R%2C%20Keong%20TC%2C%20Pongnikorn%20D%2C%20et%20al.%20Diagnostic%20work-up%20and%20systemic%20treatment%20for%20advanced%20non-squamous%20non-small-cell%20lung%20cancer%20in%20four%20Southeast%20Asian%20countries.%20ESMO%20Open.%202022%20Oct%3B7%285%29%3A100560.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20work-up%20and%20systemic%20treatment%20for%20advanced%20non-squamous%20non-small-cell%20lung%20cancer%20in%20four%20Southeast%20Asian%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Soo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Bardot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kanesvaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20C.%22%2C%22lastName%22%3A%22Keong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Pongnikorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20H.%22%2C%22lastName%22%3A%22Hutajulu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Irawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20A.%22%2C%22lastName%22%3A%22Manan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Thiagarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sripan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Storm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Stahel%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Lung%20cancer%20is%20the%20second%20most%20common%20cancer%20and%20leading%20cause%20of%20cancer%20mortality%20worldwide.%20Recent%20advances%20in%20molecular%20testing%20and%20targeted%20therapy%20have%20improved%20survival%20among%20patients%20with%20metastatic%20non-small-cell%20lung%20cancer%20%28NSCLC%29.%20We%20sought%20to%20quantify%20and%20describe%20molecular%20testing%20among%20metastatic%20non-squamous%20NSCLC%20cases%20in%20selected%20Southeast%20Asian%20countries%20and%20describe%20first-line%20therapy%20chosen.%20PATIENTS%20AND%20METHODS%3A%20A%20retrospective%20study%20was%20conducted%20based%20on%20incident%20lung%20cancer%20cases%20diagnosed%20between%202017%20and%202019%20in%20Lampang%20%28Thailand%29%2C%20Penang%20%28Malaysia%29%2C%20Singapore%20and%20Yogyakarta%20%28Indonesia%29.%20Cases%20%28n%20%3D%203413%29%20were%20defined%20using%20the%20International%20Classification%20of%20Diseases%20for%20Oncology%20third%20edition.%20In%20Singapore%2C%20a%20clinical%20series%20obtained%20from%20the%20National%20Cancer%20Centre%20was%20used%20to%20identify%20patients%2C%20while%20corresponding%20population-based%20cancer%20registries%20were%20used%20elsewhere.%20Tumor%20and%20clinical%20information%20were%20abstracted%20by%20chart%20review%20according%20to%20a%20predefined%20study%20protocol.%20Molecular%20testing%20of%20epidermal%20growth%20factor%20receptor%20%28EGFR%29%2C%20anaplastic%20lymphoma%20kinase%20%28ALK%29%20gene%20rearrangement%2C%20ROS1%20gene%20rearrangement%20and%20BRAF%20V600%20mutation%20was%20recorded.%20RESULTS%3A%20Among%202962%20cases%20with%20a%20specified%20pathological%20diagnosis%20%2886.8%25%29%2C%20most%20patients%20had%20non-squamous%20NSCLC%20%2875.8%25%29.%20For%20cases%20with%20staging%20information%20%2892.1%25%29%2C%20the%20majority%20presented%20with%20metastatic%20disease%20%2871.3%25%29.%20Overall%2C%20molecular%20testing%20rates%20in%20the%201528%20patients%20with%20stage%20IV%20non-squamous%20NSCLC%20were%2067.0%25%20for%20EGFR%2C%2042.3%25%20for%20ALK%2C%2039.1%25%20for%20ROS1%2C%207.8%25%20for%20BRAF%20and%2036.1%25%20for%20PD-L1.%20Among%20these%20patients%2C%20first-line%20systemic%20treatment%20included%20chemotherapy%20%2825.9%25%29%2C%20targeted%20therapy%20%2835.6%25%29%20and%20immunotherapy%20%285.9%25%29%2C%20with%2031%25%20of%20patients%20having%20no%20record%20of%20antitumor%20treatment.%20Molecular%20testing%20and%20the%20proportion%20of%20patients%20receiving%20treatment%20were%20highly%20heterogenous%20between%20the%20regions.%20CONCLUSIONS%3A%20This%20first%20analysis%20of%20data%20from%20a%20clinically%20annotated%20registry%20for%20lung%20cancer%20from%20four%20settings%20in%20Southeast%20Asia%20has%20demonstrated%20the%20feasibility%20of%20integrating%20clinical%20data%20within%20population-based%20cancer%20registries.%20Our%20study%20results%20identify%20areas%20where%20further%20development%20could%20improve%20patient%20access%20to%20optimal%20treatment.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2022.100560%22%2C%22ISSN%22%3A%222059-7029%20%28Electronic%29%202059-7029%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22KCH482JR%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chaiworramukkul%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BChaiworramukkul%20A%2C%20Seetalarom%20K%2C%20Saichamchan%20S%2C%20Prasongsook%20N.%20A%20Double-Blind%2C%20Placebo-Controlled%20Randomized%20Phase%20IIa%20Study%3A%20Evaluating%20the%20Effect%20of%20Curcumin%20for%20Treatment%20of%20Cancer%20Anorexia-Cachexia%20Syndrome%20in%20Solid%20Cancer%20Patients.%20Asian%20Pac%20J%20Cancer%20Prev.%202022%20July%201%3B23%287%29%3A2333%26%23x2013%3B40.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Double-Blind%2C%20Placebo-Controlled%20Randomized%20Phase%20IIa%20Study%3A%20Evaluating%20the%20Effect%20of%20Curcumin%20for%20Treatment%20of%20Cancer%20Anorexia-Cachexia%20Syndrome%20in%20Solid%20Cancer%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chaiworramukkul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Seetalarom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichamchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20aim%20to%20investigate%20the%20effect%20of%20curcumin%20on%20preventing%20cancer%20anorexia-cachexia%20syndrome%20%28CACS%29%20via%20through%20mechanism%20of%20inhibition%20on%20NF-kB%20signal%20pathway.%20Outcome%20measurement%20for%20primary%20end%20point%20was%20improvement%20of%20body%20tissue%20composition%2C%20and%20the%20secondary%20end%20points%20were%20body%20weight%20and%20body%20mass%20index%2C%20hand%20grip%20muscle%20strengthening%2C%20and%20safety.%20METHODS%3A%20This%20is%20randomized%2C%20double-blind%2C%20placebo-controlled%20phase%20ll%20a%20study%2C%2033%20patients%20with%20CACS%20in%20solid%20malignancy%20were%20enrolled%20and%20randomized%20in%201%3A1%20to%20receive%20oral%20curcumin%20%28at%20a%20dose%20of%20800%20mg%20twice%20daily%29%20or%20placebo%20for%208%20weeks.%20RESULTS%3A%20All%20parameters%20of%20body%20compositions%20were%20not%20statistically%20significant%20different%20between%20two%20groups%2C%20which%20were%20consist%20body%20fat%20mass%20%5B-1.25%28SEM%200.87%29%20vs.%20%2B0.63%28SEM%200.55%29%3B%20p%3D0.119%5D%2C%20skeletal%20muscle%20mass%20%5B-0.35%28SEM%200.60%29%20vs.%2B0.33%28SEM%200.42%29%3B%20p%3D0.408%5D%20and%20percent%20body%20fat%20%5B-0.47%28SEM%200.95%29%20vs.%20-0.29%28SEM%200.82%29%3B%20p%3D0.893%5D%20including%20with%20basal%20metabolic%20rate%20%5B-13.47%28SEM%2021.94%29%20vs.%20%2B15.30%2813.76%29%3B%20p%3D0.336%5D.%20The%20average%20of%20weight%20loss%20was%20also%20not%20statistically%20significant%20different%20between%20two%20groups.%20%5B-1.4%20kg%28SEM%200.89%29%20in%20curcumin%20vs-1.12%20kg%28SEM%200.73%29%2C%20p%3D0.810%5D.%20Notably%2C%20patient%20with%20curcumin%20had%20less%20reduction%20of%20hand-grip%20muscle%20strength%20on%20both%20hands%20%5BRt.%20handed%3A%20-2.47%20in%20curcumin%20vs.%20-5.36%20in%20placebo%3B%20p%3D0.318%5D%20%5BLt.%20handed%3A%20-1.98%20vs.%20-5.43%3B%20p%3D0.317%5D%2C%20and%20basal%20metabolic%20rate%20than%20placebo%20group.%20Most%20adverse%20events%20were%20grade%201%20on%20both%20groups%20similarly.%20CONCLUSION%3A%20Curcumin%20was%20not%20shown%20to%20be%20superior%20to%20placebo%20with%20regard%20to%20increasing%20the%20body%20composition%20in%20cancer%20patients%20with%20CACS.%20However%2C%20curcumin%20might%20show%20some%20clinical%20benefits%2C%20including%20slow%20progression%20of%20hand-grip%20muscle%20strength%20loss%2C%20and%20basal%20metabolic%20rate.%20Further%20investigations%20should%20be%20explored.%22%2C%22date%22%3A%22Jul%201%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.31557%5C%2FAPJCP.2022.23.7.2333%22%2C%22ISSN%22%3A%222476-762X%20%28Electronic%29%201513-7368%20%28Print%29%201513-7368%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22QK4IAFXB%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sainamthip%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSainamthip%20P%2C%20Saichaemchan%20S%2C%20Satirapoj%20B%2C%20Prasongsook%20N.%20The%20Effect%20of%20Intravenous%20Mannitol%20Combined%20With%20Normal%20Saline%20in%20Preventing%20Cisplatin-Induced%20Nephrotoxicity%3A%20A%20Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Trial.%20JCO%20Glob%20Oncol.%202022%20Mar%3B8%3Ae2100275.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Effect%20of%20Intravenous%20Mannitol%20Combined%20With%20Normal%20Saline%20in%20Preventing%20Cisplatin-Induced%20Nephrotoxicity%3A%20A%20Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sainamthip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Satirapoj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Nephrotoxicity%20is%20a%20major%20dose-limiting%20toxicity%20among%20patients%20with%20cancer%20who%20were%20treated%20with%20cisplatin.%20Although%20no%20standard%20approach%20is%20available%20to%20prevent%20cisplatin-induced%20nephrotoxicity%2C%20administering%20intravenous%20isotonic%20saline%20is%20recommended.%20Additionally%2C%20mannitol%20combined%20with%20hydration%20has%20been%20evaluated%2C%20but%20none%20of%20them%20have%20been%20established.%20Our%20study%20aimed%20to%20determine%20the%20efficacy%20of%20mannitol%20combined%20hydration%20to%20prevent%20cisplatin-induced%20nephrotoxicity.%20PATIENTS%20AND%20METHODS%3A%20This%20study%20was%20a%20phase%20II%2C%20randomized%2C%20placebo-controlled%20design.%20All%20patients%20with%20solid%20cancers%20who%20were%20treated%20with%20cisplatin%20%28n%20%3D%2048%29%20were%20randomly%20assigned%20to%20receive%20either%20placebo%20%28n%20%3D%2025%29%20or%2020%20g%20of%20mannitol%20%28n%20%3D%2023%29%20after%20completing%202%20L%20of%20prehydration%20and%20receiving%20cisplatin.%20Serum%20creatinine%2C%20blood%20urea%20nitrogen%2C%20electrolyte%2C%20and%20glomerular%20filtration%20rate%20%28GFR%29%20were%20measured%20at%20baseline%20and%20days%202%20and%207.%20Moreover%2C%20GFR%20was%20calculated%20based%20on%20the%2024-hour%20urine%20creatinine%20clearance%20rate%20to%20assess%20renal%20function%20at%20baseline%20and%2048%20hours%20after%20receiving%20cisplatin.%20Severity%20of%20nausea%20and%20vomiting%20was%20evaluated%20using%20Common%20Terminology%20Criteria%20for%20Adverse%20Events.%20RESULTS%3A%20No%20difference%20was%20found%20regarding%20baseline%20characteristics%20between%20the%20two%20groups.%20Seven%20of%2023%20patients%20%2837.4%25%29%20in%20the%20mannitol%20group%20and%2010%20of%2025%20patients%20%2840%25%29%20in%20the%20placebo%20group%20increased%20serum%20creatinine%20level%20%26gt%3B%5C%2F%3D%200.3%20mg%5C%2FdL%20at%2048%20hours%20after%20intervention%20%28P%20value%20%3D%20.48%29.%20Patients%20receiving%20mannitol%20exhibited%20significantly%20lower%20incidence%20of%2024-hour%20urine%20GFR%20below%2060%20mL%5C%2Fmin%5C%2F1.73%20m%20than%20those%20in%20the%20placebo%20group%20%2813.6%25%20v%2048.0%25%20in%20the%20placebo%20group%3B%20P%20value%20%3D%20.012%29.%20Univariate%20analysis%20showed%20the%20greatest%20benefit%20for%20administering%20mannitol%20among%20patients%20receiving%20cisplatin%20%26gt%3B%2080%20mg%5C%2Fm%282%29%2C%20or%20patients%20receiving%20concomitant%20radiation.%20CONCLUSION%3A%20Mannitol%20combined%20with%20hydration%20significantly%20prevented%20cisplatin-induced%20nephrotoxicity.%20Additionally%2C%20mannitol%20should%20be%20particularly%20considered%20among%20patients%20with%20cancer%2C%20treated%20with%20cisplatin%20%26gt%3B%2080%20mg%5C%2Fm%282%29%2C%20or%20patients%20receiving%20concomitant%20radiation.%22%2C%22date%22%3A%22Mar%202022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1200%5C%2FGO.21.00275%22%2C%22ISSN%22%3A%222687-8941%20%28Electronic%29%202687-8941%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22D59C7KNK%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thambamroong%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BThambamroong%20T%2C%20Seetalarom%20K%2C%20Saichaemchan%20S%2C%20Pumsutas%20Y%2C%20Prasongsook%20N.%20Efficacy%20of%20Curcumin%20on%20Treating%20Cancer%20Anorexia-Cachexia%20Syndrome%20in%20Locally%20or%20Advanced%20Head%20and%20Neck%20Cancer%3A%20A%20Double-Blind%2C%20Placebo-Controlled%20Randomised%20Phase%20IIa%20Trial%20%28CurChexia%29.%20J%20Nutr%20Metab.%202022%3B2022%3A5425619.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20Curcumin%20on%20Treating%20Cancer%20Anorexia-Cachexia%20Syndrome%20in%20Locally%20or%20Advanced%20Head%20and%20Neck%20Cancer%3A%20A%20Double-Blind%2C%20Placebo-Controlled%20Randomised%20Phase%20IIa%20Trial%20%28CurChexia%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Thambamroong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Seetalarom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Pumsutas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cancer%20anorexia-cachexia%20syndrome%20%28CAS%29%20is%20a%20significant%20comorbidity%20among%20all%20patients%20with%20cancer%2C%20increasing%20the%20mortality%20rate.%20Almost%20all%20patients%20with%20head%20and%20neck%20cancer%20experience%20this%20syndrome.%20CAS%20causes%20increased%20energy%20expenditure%20by%20increasing%20systemic%20inflammation%20and%20decreasing%20energy%20consumption%20due%20to%20anorexia.%20It%20leads%20to%20skeleton%20muscle%20breakdown%20and%20reduces%20the%20quality%20of%20life.%20Nutritional%20interventions%20and%20primary%20cancer%20treatment%20are%20the%20mainstays%20to%20manage%20this%20situation.%20However%2C%20a%20vicious%20cycle%20causes%20CAS%20to%20persist%2C%20especially%20in%20head%20and%20neck%20cancer%2C%20where%20tumour%20location%20and%20its%20treatment%20interfere%20with%20nutritional%20interventions.%20Curcumin%20shows%20anti-inflammatory%20effects%2C%20including%20modulated%20CAS%20in%20animal%20and%20in%20vitro%20studies.%20OBJECTIVE%3A%20The%20study%20aimed%20to%20determine%20the%20effect%20of%20curcumin%20to%20treat%20cancer%20anorexia-cachexia%20syndrome%20among%20current%20patients%20with%20locally%20advanced%20or%20advanced%20head%20and%20neck%20cancer.%20METHODS%3A%20This%20constitutes%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%20phase%20IIa%20study.%20Twenty%20patients%20with%20CAS%20in%20locally%20advanced%20or%20advanced%20head%20and%20neck%20cancer%20adequately%20nourished%20via%20a%20feeding%20tube%20were%20enrolled%20and%20randomised%20in%20a%201%20%3A%201%20ratio%20to%20receive%20oral%20curcumin%20%28at%20a%20dose%20of%204000%20mg%20daily%29%20%28n%20%3D%2010%29%20or%20placebo%20%28n%20%3D%2010%29%20for%208%20weeks.%20The%20primary%20endpoint%20was%20body%20composition%20%28muscle%20mass%2C%20body%20fat%20mass%2C%20and%20basal%20metabolic%20rate%29.%20The%20secondary%20endpoints%20were%20handgrip%20muscle%20strength%2C%20body%20mass%20index%2C%20absolute%20lymphocyte%20count%2C%20and%20safety%20and%20toxicity.%20RESULT%3A%20There%20was%20a%20statistically%20significant%20benefit%20from%20curcumin%20on%20improving%20muscle%20mass%20compared%20with%20placebo%20%282.16%25%20%5B95%25%20confidence%20interval%3B%20CI%2C%20-0.75%20to%205.07%5D%20vs.%20-3.82%25%20%5B95%25%20CI%2C%20-8.2%20to%200.57%5D%3B%20P%3D0.019%29.%20The%20other%20parameters%20of%20body%20composition%20were%20not%20significant%20but%20tended%20to%20favour%20curcumin%20benefit.%20The%20body%20fat%20mass%20%28-0.51%20%5B95%25%20CI%2C%20-21.89%20to%2020.86%5D%20vs.%20-8.97%25%20%5B95%25%20CI%2C%20-19.43%20to%201.49%5D%3B%20P%3D0.432%29%20and%20percentage%20of%20mean%20change%20in%20the%20basal%20metabolic%20rate%20were%20noted%20%28BMR%29%20%280.54%25%20%5B95%25%20CI%2C%20-1.6%20to%202.67%5D%20vs.%20-1.61%25%20%5B95%25%20CI%2C%20-4.05%20to%200.84%5D%3B%20P%3D0.153%29.%20Notably%2C%20patients%20treated%20with%20curcumin%20exhibited%20less%20reduction%20in%20handgrip%20muscle%20strength%20and%20absolute%20lymphocyte%20count%20but%20was%20not%20significant.%20Similarly%2C%20most%20adverse%20events%20were%20grade%201%20in%20both%20groups.%20CONCLUSION%3A%20The%20curcumin%20add-on%20resulted%20in%20a%20significant%20increase%20in%20muscle%20mass%20than%20standard%20nutritional%20support.%20Furthermore%2C%20it%20may%20improve%20and%20delay%20a%20decrease%20in%20the%20other%20body%20composition%20parameters%2C%20handgrip%20strength%2C%20and%20absolute%20lymphocyte%20count.%20Curcumin%20was%20safe%20and%20well%20tolerated.%20This%20constitutes%20an%20unmet%20need%20for%20clinical%20trials.%20This%20trial%20is%20registered%20with%20NCT04208334.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1155%5C%2F2022%5C%2F5425619%22%2C%22ISSN%22%3A%222090-0724%20%28Print%29%202090-0732%20%28Electronic%29%202090-0724%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%2232RB8MWS%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thambamroong%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BThambamroong%20T.%20The%20concordance%20between%20IHC%20and%20ISH%20for%20HER-2%20testing%20in%20breast%20cancer%20in%20Nakhon%20Pathom%20Hospital%2C%20Thailand%2C%20based%20on%20the%20ASCO%5C%2FCAP%202018%20guidelines%3A%20a%20retrospective%20study.%20Ecancermedicalscience.%202022%3B16%3A1370.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20concordance%20between%20IHC%20and%20ISH%20for%20HER-2%20testing%20in%20breast%20cancer%20in%20Nakhon%20Pathom%20Hospital%2C%20Thailand%2C%20based%20on%20the%20ASCO%5C%2FCAP%202018%20guidelines%3A%20a%20retrospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Thambamroong%22%7D%5D%2C%22abstractNote%22%3A%22Human%20epidermal%20growth%20factor%20receptor%202%20%28HER-2%29%20is%20the%20prognostic%20and%20predictive%20biomarker%20for%20breast%20cancer%20found%20in%20a%20quarter%20of%20all%20breast%20cancer%20cases.%20Precise%20testing%20of%20HER-2%20will%20impact%20treatment%20response.Based%20on%20the%20updated%20American%20Society%20of%20Clinical%20Oncology%5C%2FCollege%20of%20American%20Pathologists%20%28ASCO%5C%2FCAP%29%20HER-2%20testing%20guidelines%2C%20we%20report%20141%20cases%20of%20positive%20concordance%20rate%20between%20HER-2%20IHC%20stain%20and%20dual-probe%20ISH%20for%20HER-2%20testing%20classified%20in%20equivocal%20%282%2B%29%20and%20positive%20%283%2B%29%20IHC%20groups%20in%20Nakhon%20Pathom%20Hospital%2C%20Thailand.%20Our%20study%20showed%20statistical%20significance%20in%20the%20relationship%20between%20positive%20%283%2B%29%20IHC%20and%20dual-probe%20ISH%20for%20HER-2%20testing%20with%20a%20correlation%20rate%20of%2091.76%25%20%28r%20%28s%29%20%3D%200.38031%2C%20p%20%26lt%3B%200.0001%29%20and%2037.50%25%20in%20equivocal%20%282%2B%29%20IHC%20groups.This%20is%20the%20first%20report%20of%20a%20positive%20concordance%20rate%20between%20equivocal%20and%20positive%20HER-2%20IHC%20and%20dual-probe%20ISH%20for%20HER-2%20based%20on%20the%20ASCO%5C%2FCAP%202018%20guidelines%20in%20Thailand.%20Our%20study%20confirmed%20a%20statistically%20significant%20relationship%20in%20the%20positive%20IHC%20%283%2B%29%20group.%20In%20addition%2C%20we%20suggested%20reflexing%20ISH%20testing%20only%20in%20equivocal%20IHC%20%282%2B%29%20cases%20to%20decrease%20the%20waiting%20time%20and%20economical%20approach.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3332%5C%2Fecancer.2022.1370%22%2C%22ISSN%22%3A%221754-6605%20%28Print%29%201754-6605%20%28Electronic%29%201754-6605%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22Y99RT3FN%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Prasongsook%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPrasongsook%20N%2C%20Seetalarom%20K%2C%20Saichaemchan%20S%2C%20Udomdamrongkul%20K.%20A%20Pilot%20Study%20of%20Using%20Smartphone%20Application%20vs.%20Routine%20Follow-Up%20for%20Patient%20Care%20in%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20During%20the%20COVID-19%20Pandemic%20Era.%20Front%20Med%20Technol.%202022%3B4%3A900172.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Pilot%20Study%20of%20Using%20Smartphone%20Application%20vs.%20Routine%20Follow-Up%20for%20Patient%20Care%20in%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20During%20the%20COVID-19%20Pandemic%20Era%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Seetalarom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Udomdamrongkul%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Cancer%20care%20monitoring%20should%20be%20adapted%20regarding%20COVID-19%20pandemic%20preparedness%20plans.%20Lung%20Cancer%20Care%20application%20was%20a%20mobile%20application%20program%20to%20monitor%20adverse%20events%20and%20report%20outcomes.%20This%20study%20is%20aimed%20to%20invent%20a%20new%20mobile%20application%20evaluating%20patient-reported%20outcome%20%28PRO%29%20for%20patients%20with%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20and%20to%20evaluate%20the%20validity%20of%20a%20mobile%20application%2C%20particularly%20during%20the%20COVID-19%20pandemic%20era.%20METHODS%3A%20The%20validity%20of%20the%20application%20was%20tested%2C%20and%20Functional%20Assessment%20of%20Cancer%20Therapy-Lung%20%28FACT-L%29%20questionnaires%20were%20contained%20in%20the%20mobile%20application-based%20PRO.%20Patients%20were%20randomly%20assigned%20to%20use%20mobile%20application-based%20PRO%20vs.%20routine%20follow-up.%20The%20primary%20end%20point%20was%20to%20compare%20the%20quality%20of%20life%20%28QoL%29%20scores%20between%20two%20groups.%20A%20secondary%20end%20point%20was%20overall%20survival%20%28OS%29%20and%20the%20outcomes%20of%20progressive%20disease%20%28PD%29%20between%20the%20two%20groups.%20RESULTS%3A%20In%20total%2C%2033%20patients%20with%20advanced%20NSCLC%20were%20enrolled.%20Patients%20in%20the%20mobile%20application%20group%20had%20higher%20FACT-L%20scores%20at%203%20months%20than%20patients%20with%20a%20routine%20follow-up%20arm%20%28106%20%2B%5C%2F-%205.97%20vs.%2099.96%20%2B%5C%2F-%205.74%2C%20p-value%20%3D%200.07%29.%20The%20median%20follow-up%20time%20was%205.43%20months%3B%20patients%20with%20mobile%20application%20had%20an%20insignificant%20increase%20in%20median%20OS%20when%20compared%20with%20patients%20using%20routine%20follow-up%20%284.53%20vs.%202.93%20months%2C%20p-value%20%3D%200.85%29.%20The%20sensitivity%2C%20specificity%2C%20positive%20predictive%20value%20%28PPV%29%2C%20and%20negative%20predictive%20%28NPV%29%20value%20of%20this%20application%20for%20predicting%20disease%20progression%20were%2050%2C%2083.3%2C%2066.7%2C%20and%2070%25%2C%20respectively.%20CONCLUSION%3A%20Self-reported%20symptoms%20by%20Lung%20Cancer%20Care%20application%20improved%20QoL%20and%20were%20similar%20in%20monitoring%20outcomes%20to%20face-to-face%20follow-up.%20This%20tool%20is%20applicable%20for%20patients%20with%20cancer%20to%20make%20monitoring%20as%20safe%20as%20possible%20for%20physical%20distancing%20during%20the%20COVID-19%20pandemic%20era.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffmedt.2022.900172%22%2C%22ISSN%22%3A%222673-3129%20%28Electronic%29%202673-3129%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22DC27HNXW%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sainamthip%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSainamthip%20P%2C%20Kongphanich%20C%2C%20Prasongsook%20N%2C%20Chirapongsathorn%20S.%20Single%20dose%20dexamethasone%20prophylaxis%20of%20postembolisation%20syndrome%20after%20chemoembolisation%20in%20hepatocellular%20carcinoma%20patient%3A%20A%20randomised%2C%20double-blind%2C%20placebo-controlled%20study.%20World%20J%20Clin%20Cases.%202021%20Oct%2026%3B9%2830%29%3A9059%26%23x2013%3B69.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single%20dose%20dexamethasone%20prophylaxis%20of%20postembolisation%20syndrome%20after%20chemoembolisation%20in%20hepatocellular%20carcinoma%20patient%3A%20A%20randomised%2C%20double-blind%2C%20placebo-controlled%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sainamthip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kongphanich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chirapongsathorn%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Even%20in%20the%20immuno-oncology%20era%2C%20transcatheter%20arterial%20chemoembolisation%20%28TACE%29%20is%20the%20most%20effective%20way%20to%20treat%20intermediate%20stage%20hepatocellular%20carcinoma%20%28HCC%29.%20Postembolisation%20syndrome%20%28PES%29%20is%20the%20most%20common%20side%20effect%20from%20TACE%20and%20there%20is%20still%20no%20standard%20prevention%20guideline.%20AIM%3A%20To%20evaluate%20the%20efficacy%20of%20single%20dose%20intravenous%20dexamethasone%20regimen%20to%20prevent%20PES%20after%20TACE%20among%20patients%20with%20HCC.%20METHODS%3A%20This%20study%20enrolled%20patients%20with%20HCC%20who%20had%20eligible%20indication%20for%20TACE%20without%20macrovascular%20invasion%5C%2Fextrahepatic%20metastasis.%20Patients%20were%20randomly%20assigned%20to%20either%20an%20intravenous%20single%20dose%20of%20dexamethasone%208%20mg%20or%20placebo%20one%20hour%20before%20TACE.%20The%20primary%20outcome%20was%20a%20negative%20result%20of%20PES%20at%2048%20h%20after%20TACE%2C%20which%20was%20defined%20as%20score%20%26lt%3B%202%20of%20Southwest%20Oncology%20Group%20toxicity%20coding%20criteria%20using%20fever%2C%20nausea%2C%20vomiting%20and%20pain%20to%20calculated.%20And%20the%20secondary%20end%20point%20was%20duration%20of%20admission%20between%20two%20groups.%20RESULTS%3A%20One%20hundred%20patients%20were%20randomly%20assigned%201%3A1.%20Under%20intention-to-treat%20analysis%2C%2049%20patients%20were%20randomly%20assigned%20to%20the%20dexamethasone%20and%2051%20to%20the%20placebo%20groups.%20Both%20groups%20were%20similar%20for%20baseline%20characteristics.%20The%20negative%20PES%20rate%20was%20significantly%20higher%20in%20the%20dexamethasone%20group%20than%20in%20the%20placebo%20group%20%2863.3%25%20vs%2029.4%25%3B%20P%20%3D%200.005%29.%20Mean%20Southwest%20Oncology%20Group%20toxicity%20coding%20PES%20was%202.14%20%2895%25CI%3A%201.41-2.8%29%20vs%203.71%20%2895%25CI%3A%202.97-4.45%29%20between%20the%20dexamethasone%20and%20placebo%20groups%2C%20respectively.%20Cumulative%20incidence%20of%20fever%20was%20significantly%20lower%20in%20dexamethasone%20group%20with%20P%20%26lt%3B%200.001%2C%20pain%2C%20nausea%20and%20vomiting%20were%20also%20lower%20in%20the%20dexamethasone%20group%20compared%20with%20the%20placebo%20group%20%28P%20%3D%200.16%2C%20P%20%3D%200.11%2C%20and%20P%20%3D%200.49%29.%20The%20dexamethasone%20regimen%20was%20generally%20well%20tolerated%20by%20patients%20with%20HCC%20patients%20including%20those%20with%20hepatitis%20B%20virus%20infection%20and%20well-controlled%20diabetes%20mellitus.%20CONCLUSION%3A%20Single%20dose%20dexamethasone%20was%20effective%20at%20preventing%20PES%20among%20patients%20with%20HCC%20treated%20with%20TACE.%20The%20study%20showed%20no%20adverse%20events%20of%20special%20interest%20related%20to%20dexamethasone.%22%2C%22date%22%3A%22Oct%2026%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.12998%5C%2Fwjcc.v9.i30.9059%22%2C%22ISSN%22%3A%222307-8960%20%28Print%29%202307-8960%20%28Electronic%29%202307-8960%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22CHV4ILUP%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thambamroong%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BThambamroong%20T%2C%20Prasongsook%20N%2C%20Satayasoontorn%20K%2C%20Saichaemchan%20S.%20Extremely%20high%20alpha-fetoprotein-producing%20adrenal%20hepatoid%20adenocarcinoma.%20BMJ%20Case%20Rep.%202021%20July%2012%3B14%287%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extremely%20high%20alpha-fetoprotein-producing%20adrenal%20hepatoid%20adenocarcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Thambamroong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Satayasoontorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%5D%2C%22abstractNote%22%3A%22Hepatoid%20adenocarcinoma%20%28HAC%29%20is%20a%20rare%20tumour%20that%20produces%20an%20alpha-fetoprotein%20%28AFP%29%20mimicking%20hepatocellular%20carcinoma%20%28HCC%29.%20Adrenal%20HAC%20is%20exceedingly%20rare.%20Here%20we%20report%20extremely%20high%20AFP-producing%20adrenal%20HAC%2C%20the%20first%20case%20in%20Thailand.%20A%2047-year-old%20man%20presented%20with%20left%20flank%20pain%20and%20weight%20loss%20for%202%20months.%20A%20palpably%20huge%20left%20flank%20mass%20was%20observed%20on%20physical%20examination.%20CT%20revealed%20a%207%20cm%20enhanced%20mass%20involving%20the%20left%20adrenal%20gland%20and%20multiple%20contrast-enhanced%20hypodense%20masses%20in%20both%20liver%20lobes.%20The%20largest%20was%20a%203.7%20cm%20at%20liver%20segment-VII%20without%20cirrhotic%20background%2C%20with%20an%20AFP%20level%20of%20321%20495%20ng%5C%2FmL.%20Both%20adrenal%20and%20liver%20biopsies%20were%20performed.%20This%20patient%20received%20a%20diagnosis%20of%20advanced%20adrenal%20HAC.%20Unfortunately%2C%20the%20tumour%20progressed%2C%20causing%20massive%20upper%20gastrointestinal%20bleeding%20and%20death.%20Adrenal%20HAC%20is%20challenging%20to%20diagnose%2C%20which%20multifocal%20HCC%2C%20pheochromocytoma%20and%20adrenocortical%20carcinoma%20should%20be%20excluded.%20Surgical%20resection%20is%20preferred%20among%20resectable%20patients.%20However%2C%20no%20systemic%20therapy%20has%20been%20standardised.%22%2C%22date%22%3A%22Jul%2012%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbcr-2020-239830%22%2C%22ISSN%22%3A%221757-790X%20%28Electronic%29%201757-790X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22FIW9ARNC%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Verathamjamras%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVerathamjamras%20C%2C%20Sriwitool%20TE%2C%20Netsirisawan%20P%2C%20Chaiyawat%20P%2C%20Chokchaichamnankit%20D%2C%20Prasongsook%20N%2C%20et%20al.%20Aberrant%20RL2%20O-GlcNAc%20antibody%20reactivity%20against%20serum-IgA1%20of%20patients%20with%20colorectal%20cancer.%20Glycoconj%20J.%202021%20Feb%3B38%281%29%3A55%26%23x2013%3B65.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Aberrant%20RL2%20O-GlcNAc%20antibody%20reactivity%20against%20serum-IgA1%20of%20patients%20with%20colorectal%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Verathamjamras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20E.%22%2C%22lastName%22%3A%22Sriwitool%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Netsirisawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Chaiyawat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Chokchaichamnankit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Srisomsap%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Svasti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Champattanachai%22%7D%5D%2C%22abstractNote%22%3A%22O-GlcNAcylation%2C%20a%20single%20attachment%20of%20N-acetylglucosamine%20%28GlcNAc%29%20on%20serine%20and%20threonine%20residues%2C%20plays%20important%20roles%20in%20normal%20and%20pathobiological%20states%20of%20many%20diseases.%20Aberrant%20expression%20of%20O-GlcNAc%20modification%20was%20found%20in%20many%20types%20of%20cancer%20including%20colorectal%20cancer%20%28CRC%29.%20This%20modification%20mainly%20occurs%20in%20nuclear-cytoplasmic%20proteins%3B%20however%2C%20it%20can%20exist%20in%20some%20extracellular%20and%20secretory%20proteins.%20In%20this%20study%2C%20we%20investigated%20whether%20O-GlcNAc-modified%20proteins%20are%20present%20in%20serum%20of%20patients%20with%20CRC.%20Serum%20glycoproteins%20of%20CRC%20patients%20and%20healthy%20controls%20were%20enriched%20by%20wheat%20germ%20agglutinin%2C%20a%20glycan%20binding%20protein%20specifically%20binds%20to%20terminal%20GlcNAc%20and%20sialic%20acid.%20Two-dimensional%20gel%20electrophoresis%2C%20RL2%20O-GlcNAc%20immunoblotting%2C%20affinity%20purification%2C%20and%20mass%20spectrometry%20were%20performed.%20The%20results%20showed%20that%20RL2%20O-GlcNAc%20antibody%20predominantly%20reacted%20against%20serum%20immunoglobulin%20A1%20%28IgA1%29.%20The%20levels%20of%20RL2-reacted%20IgA%20were%20significantly%20increased%20while%20total%20IgA%20were%20not%20different%20in%20patients%20with%20CRC%20compared%20to%20those%20of%20healthy%20controls.%20Analyses%20by%20ion%20trap%20mass%20spectrometry%20using%20collision-induced%20dissociation%20and%20electron-transfer%20dissociation%20modes%20revealed%20one%20O-linked%20N-acetylhexosamine%20modification%20site%20at%20Ser%28268%29%20located%20in%20the%20heavy%20constant%20region%20of%20IgA1%3B%20unfortunately%2C%20it%20cannot%20be%20discriminated%20whether%20it%20was%20N-acetylglucosamine%20or%20N-acetylgalactosamine%20because%20of%20their%20identical%20molecular%20mass.%20Although%20failed%20to%20demonstrate%20unequivocally%20it%20was%20O-GlcNAc%2C%20these%20data%20indicated%20that%20serum-IgA%20had%20an%20aberrantly%20increased%20reactivity%20against%20RL2%20O-GlcNAc%20antibody%20in%20CRC%20patients.%20This%20specific%20glycosylated%20form%20of%20serum-IgA1%20will%20expand%20the%20spectrum%20of%20aberrant%20glycosylation%20which%20provides%20valuable%20information%20to%20cancer%20glycobiology.%22%2C%22date%22%3A%22Feb%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10719-021-09978-8%22%2C%22ISSN%22%3A%221573-4986%20%28Electronic%29%200282-0080%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%223XQ7ET37%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chantaraamporn%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-22%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BChantaraamporn%20J%2C%20Champattanachai%20V%2C%20Khongmanee%20A%2C%20Verathamjamras%20C%2C%20Prasongsook%20N%2C%20Mingkwan%20K%2C%20et%20al.%20Glycoproteomic%20Analysis%20Reveals%20Aberrant%20Expression%20of%20Complement%20C9%20and%20Fibronectin%20in%20the%20Plasma%20of%20Patients%20with%20Colorectal%20Cancer.%20Proteomes.%202020%20Sept%2022%3B8%283%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glycoproteomic%20Analysis%20Reveals%20Aberrant%20Expression%20of%20Complement%20C9%20and%20Fibronectin%20in%20the%20Plasma%20of%20Patients%20with%20Colorectal%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Chantaraamporn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Champattanachai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Khongmanee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Verathamjamras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Mingkwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Luevisadpibul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chutipongtanate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Svasti%22%7D%5D%2C%22abstractNote%22%3A%22Colorectal%20cancer%20%28CRC%29%20is%20a%20major%20cause%20of%20cancer%20mortality.%20Currently%20used%20CRC%20biomarkers%20provide%20insufficient%20sensitivity%20and%20specificity%3B%20therefore%2C%20novel%20biomarkers%20are%20needed%20to%20improve%20the%20CRC%20detection.%20Label-free%20quantitative%20proteomics%20were%20used%20to%20identify%20and%20compare%20glycoproteins%2C%20enriched%20by%20wheat%20germ%20agglutinin%2C%20from%20plasma%20of%20CRC%20patients%20and%20age-matched%20healthy%20controls.%20Among%20189%20identified%20glycoproteins%2C%20the%20levels%20of%207%20and%2015%20glycoproteins%20were%20significantly%20altered%20in%20the%20non-metastatic%20and%20metastatic%20CRC%20groups%2C%20respectively.%20Protein-protein%20interaction%20analysis%20revealed%20that%20they%20were%20predominantly%20involved%20in%20immune%20responses%2C%20complement%20pathways%2C%20wound%20healing%20and%20coagulation.%20Of%20these%2C%20the%20levels%20of%20complement%20C9%20%28C9%29%20was%20increased%20and%20fibronectin%20%28FN1%29%20was%20decreased%20in%20both%20CRC%20states%20in%20comparison%20to%20those%20of%20the%20healthy%20controls.%20Moreover%2C%20their%20levels%20detected%20by%20immunoblotting%20were%20validated%20in%20another%20independent%20cohort%20and%20the%20results%20were%20consistent%20with%20in%20the%20study%20cohort.%20Combination%20of%20CEA%2C%20a%20commercial%20CRC%20biomarker%2C%20with%20C9%20and%20FN1%20showed%20better%20diagnostic%20performance.%20Interestingly%2C%20predominant%20glycoforms%20associated%20with%20acetylneuraminic%20acid%20were%20obviously%20detected%20in%20alpha-2%20macroglobulin%2C%20haptoglobin%2C%20alpha-1-acid%20glycoprotein%201%2C%20and%20complement%20C4-A%20of%20CRC%20patient%20groups.%20This%20glycoproteomic%20approach%20provides%20invaluable%20information%20of%20plasma%20proteome%20profiles%20of%20CRC%20patients%20and%20identification%20of%20CRC%20biomarker%20candidates.%22%2C%22date%22%3A%22Sep%2022%202020%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fproteomes8030026%22%2C%22ISSN%22%3A%222227-7382%20%28Print%29%202227-7382%20%28Electronic%29%202227-7382%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22NG7CFY2U%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tienchaiananda%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTienchaiananda%20P%2C%20Nipondhkit%20W%2C%20Prasongsook%20N.%20Olanzapine%3A%20is%20it%20enough%20for%20CINV%20prevention%3F%20Ann%20Palliat%20Med.%202020%20July%3B9%284%29%3A2427%26%23x2013%3B9.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Olanzapine%3A%20is%20it%20enough%20for%20CINV%20prevention%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Tienchaiananda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Nipondhkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jul%202020%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.21037%5C%2Fapm-20-1018%22%2C%22ISSN%22%3A%222224-5839%20%28Electronic%29%202224-5820%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22CYHGHX83%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Prasongsook%20et%20al.%22%2C%22parsedDate%22%3A%222017-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPrasongsook%20N%2C%20Kumar%20A%2C%20Chintakuntlawar%20AV%2C%20Foote%20RL%2C%20Kasperbauer%20J%2C%20Molina%20J%2C%20et%20al.%20Survival%20in%20Response%20to%20Multimodal%20Therapy%20in%20Anaplastic%20Thyroid%20Cancer.%20J%20Clin%20Endocrinol%20Metab.%202017%20Dec%201%3B102%2812%29%3A4506%26%23x2013%3B14.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Survival%20in%20Response%20to%20Multimodal%20Therapy%20in%20Anaplastic%20Thyroid%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20V.%22%2C%22lastName%22%3A%22Chintakuntlawar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20L.%22%2C%22lastName%22%3A%22Foote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kasperbauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Garces%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%20N.%22%2C%22lastName%22%3A%22Wittich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Rubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Richardson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Fatourechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22McIver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ryder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Richards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20J.%22%2C%22lastName%22%3A%22Sebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Rivera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Suman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20M.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Smallridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20C.%22%2C%22lastName%22%3A%22Bible%22%7D%5D%2C%22abstractNote%22%3A%22CONTEXT%3A%20Historical%20outcomes%20in%20anaplastic%20thyroid%20cancer%20%28ATC%29%20have%20been%20dismal.%20OBJECTIVE%3A%20To%20determine%20whether%20an%20initial%20intensive%20multimodal%20therapy%20%28MMT%29%20is%20associated%20with%20improved%20ATC%20survival.%20DESIGN%3A%20MMT%20was%20offered%20to%20all%20patients%20with%20newly%20diagnosed%20ATC%20treated%20at%20the%20Mayo%20Clinic%20from%202003%20through%202015%3B%20MMT%20vs%20care%20with%20palliative%20intent%20%28PI%29%20was%20individualized%20considering%20clinical%20status%20and%20patient%20preferences.%20Outcomes%20were%20retrospectively%20analyzed%20by%20American%20Joint%20Committee%20on%20Cancer%20stage%20and%20treatments%20compared%20with%20patient%20cohort%20data%20from%201949%20through%201999.%20PATIENTS%3A%20Forty-eight%20patients%20%2860%25%20male%3B%20median%20age%2C%2062%20years%29%3B%2018%20treated%20with%20PI%2C%2030%20with%20MMT.%20MAIN%20OUTCOME%20MEASURE%3A%20Overall%20survival%20%28OS%29%20and%20progression-free%20survival%20determined%20by%20Kaplan-Meier%20method.%20RESULTS%3A%20Median%20OS%20and%201-year%20survival%20for%20the%20later%20cohort%20were%209%20months%20%5B95%25%20confidence%20interval%20%28CI%29%2C%204%20to%2022%20months%5D%20and%2042%25%20%2895%25%20CI%2C%2028%25%20to%2056%25%29%20vs%203%20months%20and%2010%25%20for%20the%20earlier%20cohort.%20Median%20OS%20was%2021%20months%20compared%20with%203.9%20months%20in%20the%20pooled%20MMT%20vs%20PI%20groups%20for%20the%20later%20cohort%20%5Bhazard%20ratio%20%28HR%29%2C%200.32%3B%20P%20%3D%200.0006%5D.%20Among%20only%20patients%20in%20the%20later%20cohort%20who%20had%20stage%20IVB%20disease%2C%20median%20OS%20was%2022.4%20vs%204%20months%20%28HR%2C%200.12%3B%2095%25%20CI%2C%200.03%20to%200.44%3B%20P%20%3D%200.0001%29%2C%20with%2068%25%20vs%200%25%20alive%20at%201%20year%20%28MMT%20vs%20PI%29.%20Among%20patients%20with%20stage%20IVC%20cancer%2C%20OS%20did%20not%20differ%20by%20therapy.%20CONCLUSION%3A%20MMT%20appears%20to%20convey%20longer%20survival%20in%20ATC%20among%20patients%20with%20stage%20IVA%5C%2FB%20disease.%22%2C%22date%22%3A%22Dec%201%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1210%5C%2Fjc.2017-01180%22%2C%22ISSN%22%3A%221945-7197%20%28Electronic%29%200021-972X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A46Z%22%7D%7D%2C%7B%22key%22%3A%2247EEL3HH%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Turner%20et%20al.%22%2C%22parsedDate%22%3A%222017-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTurner%20J%2C%20Couts%20K%2C%20Sheren%20J%2C%20Saichaemchan%20S%2C%20Ariyawutyakorn%20W%2C%20Avolio%20I%2C%20et%20al.%20Kinase%20gene%20fusions%20in%20defined%20subsets%20of%20melanoma.%20Pigment%20Cell%20Melanoma%20Res.%202017%20Jan%3B30%281%29%3A53%26%23x2013%3B62.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Kinase%20gene%20fusions%20in%20defined%20subsets%20of%20melanoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Couts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Sheren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Ariyawutyakorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Avolio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cabral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Glogowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Robinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Hintzsche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Applegate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Seelenfreund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bagby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tentler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Wisell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Varella-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Robinson%22%7D%5D%2C%22abstractNote%22%3A%22Genomic%20rearrangements%20resulting%20in%20activating%20kinase%20fusions%20have%20been%20increasingly%20described%20in%20a%20number%20of%20cancers%20including%20malignant%20melanoma%2C%20but%20their%20frequency%20in%20specific%20melanoma%20subtypes%20has%20not%20been%20reported.%20We%20used%20break-apart%20fluorescence%20in%20situ%20hybridization%20%28FISH%29%20to%20identify%20genomic%20rearrangements%20in%20tissues%20from%2059%20patients%20with%20various%20types%20of%20malignant%20melanoma%20including%20acral%20lentiginous%2C%20mucosal%2C%20superficial%20spreading%2C%20and%20nodular.%20We%20identified%20four%20genomic%20rearrangements%20involving%20the%20genes%20BRAF%2C%20RET%2C%20and%20ROS1.%20Of%20these%2C%20three%20were%20confirmed%20by%20Immunohistochemistry%20%28IHC%29%20or%20sequencing%20and%20one%20was%20found%20to%20be%20an%20ARMC10-BRAF%20fusion%20that%20has%20not%20been%20previously%20reported%20in%20melanoma.%20These%20fusions%20occurred%20in%20different%20subtypes%20of%20melanoma%20but%20all%20in%20tumors%20lacking%20known%20driver%20mutations.%20Our%20data%20suggest%20gene%20fusions%20are%20more%20common%20than%20previously%20thought%20and%20should%20be%20further%20explored%20particularly%20in%20melanomas%20lacking%20known%20driver%20mutations.%22%2C%22date%22%3A%22Jan%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fpcmr.12560%22%2C%22ISSN%22%3A%221755-148X%20%28Electronic%29%201755-1471%20%28Print%29%201755-1471%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22M9E2SHVV%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ariyawutyakorn%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAriyawutyakorn%20W%2C%20Saichaemchan%20S%2C%20Varella-Garcia%20M.%20Understanding%20and%20Targeting%20MET%20Signaling%20in%20Solid%20Tumors%20-%20Are%20We%20There%20Yet%3F%20J%20Cancer.%202016%3B7%286%29%3A633%26%23x2013%3B49.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Understanding%20and%20Targeting%20MET%20Signaling%20in%20Solid%20Tumors%20-%20Are%20We%20There%20Yet%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Ariyawutyakorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Varella-Garcia%22%7D%5D%2C%22abstractNote%22%3A%22The%20MET%20signaling%20pathway%20plays%20an%20important%20role%20in%20normal%20physiology%20and%20its%20deregulation%20has%20proved%20critical%20for%20development%20of%20numerous%20solid%20tumors.%20Different%20technologies%20have%20been%20used%20to%20investigate%20the%20genomic%20and%20proteomic%20status%20of%20MET%20in%20cancer%20patients%20and%20its%20association%20with%20disease%20prognosis.%20Moreover%2C%20with%20the%20development%20of%20targeted%20therapeutic%20drugs%2C%20there%20is%20an%20urgent%20need%20to%20identify%20potential%20biomarkers%20for%20selection%20of%20patients%20who%20are%20more%20likely%20to%20derive%20benefit%20from%20these%20agents.%20Unfortunately%2C%20the%20variety%20of%20technical%20platforms%20and%20analysis%20criteria%20for%20diagnosis%20has%20brought%20confusion%20to%20the%20field%20and%20a%20lack%20of%20agreement%20in%20the%20evaluation%20of%20MET%20status%20as%20a%20prognostic%20or%20predictive%20marker%20for%20targeted%20therapy%20agents.%20We%20review%20the%20molecular%20mechanisms%20involved%20in%20the%20deregulation%20of%20the%20MET%20signaling%20pathway%20in%20solid%20tumors%2C%20the%20different%20technologies%20used%20for%20diagnosis%2C%20and%20the%20main%20factors%20that%20affect%20the%20outcome%2C%20emphasizing%20the%20urge%20for%20completing%20analytical%20and%20clinical%20validation%20of%20these%20tests.%20We%20also%20review%20the%20current%20clinical%20studies%20with%20MET%20targeted%20agents%2C%20which%20mostly%20focus%20on%20lung%20cancer.%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.7150%5C%2Fjca.12663%22%2C%22ISSN%22%3A%221837-9664%20%28Print%29%201837-9664%20%28Electronic%29%201837-9664%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22IWPCY8GR%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Saichaemchan%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSaichaemchan%20S%2C%20Ariyawutyakorn%20W%2C%20Varella-Garcia%20M.%20Fibroblast%20Growth%20Factor%20Receptors%3A%20From%20the%20Oncogenic%20Pathway%20to%20Targeted%20Therapy.%20Curr%20Mol%20Med.%202016%3B16%281%29%3A40%26%23x2013%3B62.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fibroblast%20Growth%20Factor%20Receptors%3A%20From%20the%20Oncogenic%20Pathway%20to%20Targeted%20Therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Saichaemchan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Ariyawutyakorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Varella-Garcia%22%7D%5D%2C%22abstractNote%22%3A%22The%20family%20of%20fibroblast%20growth%20factor%20%28FGFs%29%20and%20their%20receptors%20%28FGFRs%29%20regulates%20vital%20roles%20in%20many%20biological%20processes%20affecting%20cell%20proliferation%2C%20migration%2C%20differentiation%20and%20survival.%20Deregulation%20of%20the%20FGF%5C%2FFGFR%20signaling%20pathway%20in%20cancers%20has%20been%20better%20understood%20and%20the%20main%20molecular%20mechanisms%20responsible%20for%20the%20activation%20of%20this%20pathway%20are%20gene%20mutations%2C%20gene%20fusions%20and%20gene%20amplification.%20DNA%20and%20RNA-based%20technologies%20have%20been%20used%20to%20detect%20these%20abnormalities%2C%20especially%20in%20FGFR1%2C%20FGFR2%20and%20FGFR3%20and%20tests%20have%20been%20developed%20for%20their%20detection%2C%20but%20no%20assay%20has%20been%20proved%20ideal%20for%20molecular%20diagnosis.%20Interestingly%2C%20the%20increase%20in%20the%20molecular%20biology%20knowledge%20has%20supported%20and%20assisted%20the%20development%20of%20therapeutic%20drugs%20targeting%20the%20most%20important%20components%20of%20this%20pathway.%20Multi-%20and%20selective%20tyrosine%20kinase%20inhibitors%20%28TKIs%29%20as%20well%20as%20monoclonal%20antibodies%20anti-FGFR%20are%20under%20investigation%20in%20preclinical%20and%20clinical%20trials.%20In%20this%20article%2C%20we%20reviewed%20those%20aspects%20with%20special%20emphasis%20on%20the%20pathway%20genomic%20alterations%20related%20to%20solid%20tumors%2C%20and%20the%20molecular%20diagnostic%20assays%20potentially%20able%20to%20stratify%20patients%20for%20the%20treatment%20with%20FGFR%20TKIs.%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2174%5C%2F1566524016666151222144231%22%2C%22ISSN%22%3A%221875-5666%20%28Electronic%29%201566-5240%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22H8HWZ9RP%22%2C%22library%22%3A%7B%22id%22%3A6104509%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chaisakul%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BChaisakul%20J%2C%20Hodgson%20WC%2C%20Kuruppu%20S%2C%20Prasongsook%20N.%20Effects%20of%20Animal%20Venoms%20and%20Toxins%20on%20Hallmarks%20of%20Cancer.%20J%20Cancer.%202016%3B7%2811%29%3A1571%26%23x2013%3B8.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20Animal%20Venoms%20and%20Toxins%20on%20Hallmarks%20of%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Chaisakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Hodgson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kuruppu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Prasongsook%22%7D%5D%2C%22abstractNote%22%3A%22Animal%20venoms%20are%20a%20cocktail%20of%20proteins%20and%20peptides%2C%20targeting%20vital%20physiological%20processes.%20Venoms%20have%20evolved%20to%20assist%20in%20the%20capture%20and%20digestion%20of%20prey.%20Key%20venom%20components%20often%20include%20neurotoxins%2C%20myotoxins%2C%20cardiotoxins%2C%20hematoxins%20and%20catalytic%20enzymes.%20The%20pharmacological%20activities%20of%20venom%20components%20have%20been%20investigated%20as%20a%20source%20of%20potential%20therapeutic%20agents.%20Interestingly%2C%20a%20number%20of%20animal%20toxins%20display%20profound%20anticancer%20effects.%20These%20include%20toxins%20purified%20from%20snake%2C%20bee%20and%20scorpion%20venoms%20effecting%20cancer%20cell%20proliferation%2C%20migration%2C%20invasion%2C%20apoptotic%20activity%20and%20neovascularization.%20Indeed%2C%20the%20mechanism%20behind%20the%20anticancer%20effect%20of%20certain%20toxins%20is%20similar%20to%20that%20of%20agents%20currently%20used%20in%20chemotherapy.%20For%20example%2C%20Lebein%20is%20a%20snake%20venom%20disintegrin%20which%20generates%20anti-angiogenic%20effects%20by%20inhibiting%20vascular%20endothelial%20growth%20factors%20%28VEGF%29.%20In%20this%20review%20article%2C%20we%20highlight%20the%20biological%20activities%20of%20animal%20toxins%20on%20the%20multiple%20steps%20of%20tumour%20formation%20or%20hallmarks%20of%20cancer.%20We%20also%20discuss%20recent%20progress%20in%20the%20discovery%20of%20lead%20compounds%20for%20anticancer%20drug%20development%20from%20venom%20components.%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.7150%5C%2Fjca.15309%22%2C%22ISSN%22%3A%221837-9664%20%28Print%29%201837-9664%20%28Electronic%29%201837-9664%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-18T14%3A46%3A45Z%22%7D%7D%5D%7D
1.
Thambamroong T, Seetalarom K, Saichaemchan S, Peechatanan K, Phavirunsiri J, Prasongsook N. IMPROVING QUALITY OF LIFE IN LOCALLY ADVANCED OR ADVANCED HEAD AND NECK CANCER WITH CURCUMIN ADD-ON TO STANDARD NUTRITION SUPPORT: A SECONDARY ANALYSIS OF THE CURCHEXIA STUDY. J Southeast Asian Med Res [Internet]. 2025 Sept 9 [cited 2025 Sept 15];9:e0234. Available from: https://www.jseamed.org/index.php/jseamed/article/view/234
1.
Shuangshoti S, Prasongsook N, Thamlikitkul L, Reungwetwattana T, Poungvarin N, Jinawath A, et al. Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand. Transl Lung Cancer Res. 2025 July 31;14(7):2387–402.
1.
Kanesvaran R, Wong EYT, Keam B, Prasongsook N, Malhotra H, Blay JY. Quality-of-care indicators for oncology management: an analysis of Asia-Pacific healthcare and oncology indicators. ESMO Open. 2025 Mar;10(3):104293.
1.
Crona J, Lee R, Sobczuk P, Wysoki O, Devnani B, Prasongsook N, et al. Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society. ESMO Open. 2024 May;9(5):102531.
1.
Gobbo M, Joy J, Guedes H, Shazib MA, Anderson C, Abdalla-Aslan R, et al. Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents. Expert Opin Pharmacother. 2024 Apr;25(6):727–42.
1.
Thambamroong T, Rabiltossaporn C. Biallelic MUTYH gene mutation resulting in fluoropyrimidine-resistant advanced rectal cancer: A case report. TD [Internet]. 2024;4(1). Available from: {https://accscience.com//journal/TD/4/1/10.36922/td.5164}
1.
Loong HH, Shimizu T, Prawira A, Tan AC, Tran B, Day D, et al. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. ESMO Open. 2023 Aug;8(4):101586.
1.
Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023 June;8(3):101558.
1.
Pornrattanakavee P, Srichan T, Seetalarom K, Saichaemchan S, Oer-Areemitr N, Prasongsook N. Impact of interprofessional collaborative practice in palliative care on outcomes for advanced cancer inpatients in a resource-limited setting. BMC Palliat Care. 2022 Dec 29;21(1):229.
1.
Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, et al. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. Clin Lung Cancer. 2022 Dec;23(8):670–85.
1.
Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, Payapwattanawong S, Siripoon T, Pakvisal N, et al. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study. JCO Glob Oncol. 2022 Nov;8:e2200205.
1.
Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, et al. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO Open. 2022 Oct;7(5):100560.
1.
Chaiworramukkul A, Seetalarom K, Saichamchan S, Prasongsook N. A Double-Blind, Placebo-Controlled Randomized Phase IIa Study: Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Solid Cancer Patients. Asian Pac J Cancer Prev. 2022 July 1;23(7):2333–40.
1.
Sainamthip P, Saichaemchan S, Satirapoj B, Prasongsook N. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. JCO Glob Oncol. 2022 Mar;8:e2100275.
1.
Thambamroong T, Seetalarom K, Saichaemchan S, Pumsutas Y, Prasongsook N. Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia). J Nutr Metab. 2022;2022:5425619.
1.
Thambamroong T. The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a retrospective study. Ecancermedicalscience. 2022;16:1370.
1.
Prasongsook N, Seetalarom K, Saichaemchan S, Udomdamrongkul K. A Pilot Study of Using Smartphone Application vs. Routine Follow-Up for Patient Care in Advanced Non-Small Cell Lung Cancer During the COVID-19 Pandemic Era. Front Med Technol. 2022;4:900172.
1.
Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases. 2021 Oct 26;9(30):9059–69.
1.
Thambamroong T, Prasongsook N, Satayasoontorn K, Saichaemchan S. Extremely high alpha-fetoprotein-producing adrenal hepatoid adenocarcinoma. BMJ Case Rep. 2021 July 12;14(7).
1.
Verathamjamras C, Sriwitool TE, Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Prasongsook N, et al. Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer. Glycoconj J. 2021 Feb;38(1):55–65.
1.
Chantaraamporn J, Champattanachai V, Khongmanee A, Verathamjamras C, Prasongsook N, Mingkwan K, et al. Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer. Proteomes. 2020 Sept 22;8(3).
1.
Tienchaiananda P, Nipondhkit W, Prasongsook N. Olanzapine: is it enough for CINV prevention? Ann Palliat Med. 2020 July;9(4):2427–9.
1.
Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4506–14.
1.
Turner J, Couts K, Sheren J, Saichaemchan S, Ariyawutyakorn W, Avolio I, et al. Kinase gene fusions in defined subsets of melanoma. Pigment Cell Melanoma Res. 2017 Jan;30(1):53–62.
1.
Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer. 2016;7(6):633–49.
1.
Saichaemchan S, Ariyawutyakorn W, Varella-Garcia M. Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med. 2016;16(1):40–62.
1.
Chaisakul J, Hodgson WC, Kuruppu S, Prasongsook N. Effects of Animal Venoms and Toxins on Hallmarks of Cancer. J Cancer. 2016;7(11):1571–8.